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FEASIBILITY OF USING VIRTUAL UNENHANCED IMAGES TO REPLACE PRECONTRAST IMAGES IN MULTIPHASE RENAL CT EXAMINATIONS

Dawn Olivia Popnoe, B.S.
Advisory Professor: Kyle Jones, Ph.D.

Multiphase renal CT exams are a commonly used imaging technique for the diagnosis of
renal masses. The pre-contrast, or true unenhanced (TUE), image provides a baseline for
enhancement measurements which is an important criteria used to characterize renal lesions,
consequently it is crucial that CT numbers measured in TUE images be accurate. The purpose of
this work is to assess the feasibility of replacing TUE with virtual unenhanced (VUE) images
derived from DECT data in renal CT exams. Eliminating TUE image acquisition would reduce
patient dose and increase patient throughput, improving clinical efficiency.
A retrospective study was conducted for 60 consecutively selected patient exams. VUE
and TUE images were compared qualitatively and the differences were tested using a Bayesian
Hierarchical model. VUE images were found to be inferior to TUE images for visualization of
major vessels and depiction of liver parenchyma. CT numbers were measured in the liver, spleen,
spine, aorta, cystic lesions, subcutaneous fat, renal cortex and medulla, and the differences were
tested with a Student’s paired t-test. There were significant differences between TUE and VUE
measurements ( p-value > 0.05) in the spleen, spine, aorta, renal cortex, subcutaneous fat, and
inferior vena cava. However, evaluation of the clinical relevance based on grayscale perceptibly
indicated that the difference for the spleen and subcutaneous fat are not clinically meaningful.
The rapid kVp-switching GE CT750HD scanner was used to assess enhancement
accuracy when using VUE compare to TUE images as the baseline for enhancement calculations
v

across a wide range of clinical scenarios simulated in a phantom study, and the results were
analyzed using Bayesian Hierarchical models. For simulation of angiomyolipoma and benign
cystic lesions, enhancement values were not significantly different. However, for simulation of
Bosniak category II-IV lesions, differences in measured enhancement were found to be
significant. Additionally, the effect of ASIR level used in image reconstruction was assessed, and
found not to affect measured CT number using a mixed effects model.
Differences in measured enhancement values for simulated borderline enhancing renal
lesions demonstrate that replacement of TUE with VUE images is not feasible with the current
iteration of the algorithm.
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Chapter 1. Introduction and Background
1.1 Computed Tomography
Computed Tomography (CT) is a commonly used imaging technique in volumetric
dataset of the patient anatomy is acquired and reconstructed to provide a three-dimensional
representation of the linear attenuation coefficients contained within each voxel in the field of
view (FOV). This imaging modality provides a non-invasive method for patient diagnosis, and is
performed annually around 70 – 80 million times in the United States [1]. First introduced in
clinical practice in 1972, CT has since revolutionized both medical imaging and the practice of
medicine [2].
1.1.1 Single Energy Computed Tomography
Single Energy Computed Tomography (SECT), commonly referred to as conventional
CT, is based on the fact that each material within the CT field of view (FOV) has a characteristic
linear attenuation curve, which in turn dictates the ways in which each material interacts with an
X-ray beam. CT images are reconstructed from line integral measurements of X-ray attenuation
through the human body using mathematical concepts first discussed by Johann Radon in 1917
[2].
The primary modes for X-ray interaction in the energy range used for diagnostic CT
imaging are the photoelectric effect and incoherent (Compton) scattering. The photoelectric effect
occurs when an incident X-ray photon transfers all of its energy to an inner shell atomic electron,
which is then ejected from the atom. The probability of this interaction is approximately
proportional to the atomic number cubed and inversely proportional the energy cubed [1]. This
energy dependence, in conjunction with differences in K absorption edges of different atomic
elements, is a fundamental concept facilitating the dual energy technique [3]. Incoherent
scattering refers to the interaction of an incident photon with a valence electron, where the
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electron is ejected from the atom, and the photon is scattered with a fraction of its initial energy.
This is the predominant interaction mechanism in the diagnostic energy range above 26 keV [1].
In contrast to the photoelectric effect, Compton scatter is almost independent of photon energy,
and instead is strongly dependent on the electron density of a material.
An X-ray source that is contained within the CT scanner produces a spectrum of X-rays
with a peak kilovoltage (kVp) typically ranging between 80 – 140, and a corresponding array of
detectors is aligned opposite of the X-ray source [1]. During data acquisition, the X-ray source
and detector array rotate synchronously around the axis of the gantry. Originally, CT images were
acquired with axial scanning, which involves the translation of the object to be imaged along the
z-axis of the scanner between sequential cycles of the gantry, resulting in the reconstruction of
one or more images per rotation, depending on the number of detector rows. Helical CT defines a
mode of operation in which the object to be imaged is translated along the z-axis while the X-ray
source is rotating, resulting in the volumetric set of line integrals of attenuation through the
object. Interpolation is then used to produce sets of coplanar projections from the threedimensional data set which are then reconstructed into image sets using filtered back projection or
iterative reconstruction [4]. In either case, the images produced are attenuation maps of the
materials and tissues contained within the field of view (FOV), each having a characteristic linear
attenuation coefficient, 𝜇, which is dependent on photon energy and therefore kV and beam
filtration [5]. The image is comprised of an array of voxels, each with a gray scale value based on
the X-ray attenuation within that voxel. The gray scale value is referred to as a Hounsfield Unit
(HU) and is defined as [1]:
𝐻𝑈(𝑥, 𝑦, 𝑧) = 1000 ∗ (

2

𝜇(𝑥,𝑦,𝑧)−𝜇𝑤
)
𝜇𝑤

Equation 1.1.1-1

where 𝜇(x,y,z) is the average linear attenuation coefficient measured in a voxel located at (x,y,z)
within the patient and 𝜇w is the linear attenuation coefficient of water. This provides a relative
attenuation measurement in which the attenuation is scaled to that of water (HU=0).
1.1.2 Dual Energy Computed Tomography
Dual Energy Computed Tomography (DECT) is an extension of SECT in which two data
sets are acquired using different X-ray energy spectra. DECT was originally proposed in the late
1970s, but technical limitations of early CT scanners limited the success of the technique [1, 6-9].
DECT was abandoned because the acquisition times of early scanners were long and two
consecutive scans were needed which led to motion misregistration between data sets, as well as
additional radiation exposure [9]. With the advanced capabilities of newer scanners, there has
been renewed interest in the clinical use of DECT. One potential benefit of this technique is that it
can provide information regarding the material composition within each voxel by exploiting
attenuation variations of photon absorption at different energies as well as attenuation differences
of materials with high atomic numbers [9]. In addition to enhancing material differentiation,
DECT has the potential to reduce beam hardening artifacts [8].
DECT has the potential to expand the capabilities of CT by allowing for the estimation of
the linear attenuation curve for each voxel in the object, providing both spatial and material
information, as opposed to only a spatial map of scalar HU values [10]. This is accomplished by
measuring the attenuation of materials in the FOV using two different effective X-ray energies
and then extrapolating, using knowledge of the exponential behavior of X-ray attenuation of
materials, to estimate the full attenuation curve. This curve can then be compared to known
attenuation curves to gain information as to composition of the material.
The foundation of this material decomposition technique exploits the fact that the
attenuation coefficient for a given material is a function of a unique combination of photoelectric
and incoherent scattering probabilities, which are related to effective atomic number and electron
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density, respectively. For a given material, the attenuation coefficient as a function of energy µ(E)
may then be represented as a unique combination of photoelectric and incoherent scatter
coefficients:
𝜇(𝐸) = 𝛼𝑓𝑃𝐸 + 𝛽𝑓𝐶

Equation 1.1.2-1

where fPE represents the photoelectric dependence, which depends strongly on atomic number and
therefore provides information as to the composition of the object, and fC represents the Compton
scatter coefficient, which depends strongly on electron density and is therefore proportional to
mass density [11]. The weighted linear combination of these two coefficients can represent the
mass attenuation coefficient of any material in the diagnostic energy range [12]. However,
discontinuities at the K-edge of a material can complicate the simplified assumption that this is a
linear combination. Consider as an example iodine, which is commonly used as a contrast agent
in diagnostic imaging due to its 33.2 keV K-edge. If the effective energy of the beam is just above
this K-edge, the probability of photoelectric interaction (fPE) will be approximately six times
greater than the probability for energies just below the K-edge, 33.1 keV [1].
Following on this technique, a basis pair of two materials may be chosen, such that all
materials contained within a given voxel in a DECT image are assumed to be a weighted
combination of the selected basis pair, e.g., water and iodine. Note that it is crucial that the
selected materials differ substantially in atomic number and electron density so that they
consequently differ in photoelectric and incoherent scatter attenuation cross sections, resulting in
a large separation between the linear attenuation curves. The total linear attenuation coefficient in
any voxel can be expressed as a weighted combination of the attenuation of basis materials 1 and
2:
𝜇(𝐸) = 𝛿1 ∗ 𝜇1 (𝐸) + 𝛿2 ∗ 𝜇2 (𝐸)
where
4

Equation 1.1.2-2

𝜇1 (𝐸) = 𝛼1 𝑓𝑃𝐸 + 𝛽1 𝑓𝐶 𝑎𝑛𝑑 𝜇2 (𝐸) = 𝛼2 𝑓𝑃𝐸 + 𝛽2 𝑓𝐶

Equation 1.1.2-3

In Equation 1.1.2-2 the variable δi represents the weighting of the corresponding basis material
such that the combination of weighted attenuation from each material in the basis pair yields the
measured attenuation of the material in the voxel. The system of equations given in Equation
1.1.2-3 can be solved for fPE and fC:
𝜇 𝛽 −𝜇 𝛽

𝑓𝑃𝐸 = 𝛼2 𝛽1 −𝛼1 𝛽2
2 1

Equation 1.1.2-4

1 2

𝜇 𝛼 −𝜇 𝛼

𝑓𝐶 = 𝛼2 𝛽1 −𝛼1 𝛽2
1 2

Equation 1.1.2-5

2 1

Substituting Equations 1.1.2-4 and 1.1.2-5 into Equation 1.1.2-3 followed by 1.1.2-2 and then
rearranging yields:
𝜇 𝛽 −𝜇 𝛽

𝜇 𝛼 −𝜇 𝛼

𝜇 𝛽 −𝜇 𝛽

𝜇 𝛼 −𝜇 𝛼

𝜇(𝐸) = 𝛿1 [𝛼1 (𝛼2 𝛽1 −𝛼1 𝛽2 ) + 𝛽1 (𝛼2 𝛽1 −𝛼1 𝛽2 )] + 𝛿2 [𝛼2 (𝛼2 𝛽1 −𝛼1 𝛽2 ) + 𝛽2 (𝛼2 𝛽1 −𝛼1 𝛽2 )]
2 1

1 2

1 2

2 1

2 1

1 2

1 2

2 1

Equation 1.1.2-6
Equation 1.1.2-6 represents the attenuation coefficient for any material as a weighted combination
of the selected basis pair. All subscripts 1 correspond to attenuation properties of the first basis
material, and subscripts 2 correspond to the second basis material. Attenuation data can then be
measured at two different effective X-ray energies, resulting in two equations (equation 1.1.2-6 at
the high and low energy), µL and µH, with two unknowns, δ1 and δ2. Each unknown variable, δi,
represents the fraction of the material within the voxel attributed to each of the basis materials.
Line integrals can then be taken over the linear attenuation coefficient for each ray of each
projection and corresponding detector element and used to make measurements of the function
being reconstructed to generate an image [11]. The resulting intensity equations can then be
solved for δ1 and δ2, which are the weightings that combine to yield the unique attenuation of the
material in the voxel. An example of material decomposition with a basis pair of water and iodine
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for a voxel containing bone is shown in Figure 1. The light blue line indicates the estimated
weighted combination of water and iodine attenuation coefficients, as described.

Figure 1. Bone material attenuation coefficient represented as a weighted combination of
water and iodine attenuation coefficients [13]
There are two commonly used techniques for DECT data acquisition. The first is a dualsource technique that involves the use of two X-ray sources mounted nearly 900 apart, a concept
that was first proposed only a few years after CT was first introduced into clinical practice and
then re-introduced in 2006 [7]. A benefit of this technique is that the tube current (mA) can be
selected independently for each X-ray source, which ensures similar X-ray fluence at both beam
energies. This system also offers the potential for increased separation between the two energy
spectra by filtering the high energy X-ray source which increases the contrast between two
materials and therefore improves the performance of DECT algorithms [7]. Disadvantages of this
technique include a limited DECT scan field of view (SFOV) resulting from the smaller coverage
of the second detector array and cross scatter between non-corresponding orthogonal detector
rows [7]. Additionally, the angular separation of the X-ray sources results in a temporal
difference on the order of 100 milliseconds between the high and low energy projections, which
can introduce artifacts from patient motion and result in mis-registration of the two data sets [7].
The second technique currently used for commercial DECT data acquisition involves a
single X-ray source with fast kVp switching. For this technique, the high voltage generator
6

alternates between high and low kVp at each projection angle, creating an interleaved set of high
and low energy projections. The nearly simultaneous acquisition of the two data sets results in
better temporal registration, which reduces the potential for motion artifacts while still using the
entire SFOV for DECT [8]. Fast switching between two kVps does have technical challenges,
including the rise and fall times of the high voltage waveforms, which complicates the
determination of the effective energy for the high and low kVp projections [14]. Because this rise
and fall of the waveforms occurs during data acquisition, it reduces the achievable separation
between the energy spectra [7]. Another consequence of this technique, which uses a single
detector array, is that the view integration time is limited by the primary decay of the detector and
afterglow performance [8]. The Gemstone scintillator (General Electric Healthcare, Milwaukee,
WI) has been developed to minimize this integration time limitation, as it has a decay time of 30
ns which is 100 times faster than the more commonly used gadolinium oxysulfide (Gd2O2S) and
afterglow levels that reach only 25% of gadolinium oxysulfide [8]. Energy separation is further
limited by the use of a single source to produce both spectra, as it is not possible to filter the high
energy spectrum as describe previously for the dual source technique.
The GE HD750 (General Electric Medical Systems, Milwaukee, WI) is a commercially
available DECT scanner that uses the rapid kVp switching technique. This system includes
analysis software, the GSI [Gemstone Spectral Imaging] Volume Viewer (General Electric
Healthcare, Milwaukee, WI), that allows for two material basis pair decomposition image sets to
be reconstructed based on a user selected material basis pair. This system also includes MSI
[Material Suppressed Iodine] analysis software that allows for the reconstruction of Virtual
Unenhanced (VUE) images in which the iodine volume is replaced with an equivalent volume of
blood to generate a virtual non-contrast data set from data acquired after the administration of
iodine contrast. The focus of this study will be on assessing the functional capabilities of these
VUE images generated from MSI software.
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1.2 Classification of renal lesions
Abdominal multiphase CT exams are a commonly used non-invasive imaging technique
for the classification of renal lesions [15]. The CT exams are often used to distinguish hyperattenuating renal cysts from enhancing renal masses after a contrast agent is administered
intravenously [3]. Multiphase renal CT exams include a non-contrast phase which is followed by
the administration of a contrast agent, typically iodine based, and one or more post-contrast
imaging phases. Iodine is commonly used as the contrast agent due to the high contrast it offers
relative to the tissues in the human body. Enhancement can be quantified by comparing the
measured CT number of a lesion in the non-contrast image to the measured CT number of the
same lesion in the post-contrast image. Previously a difference of 10 HU between non-contrast
and post-contrast images was the minimum criterion for enhancement [16]. However, with the
advent of helical CT it has been suggested that this threshold of 10 HU should be increased to
account for artifacts from helical interpolation, and enhancement is currently characterized
definitively as a change in CT number of approximately 20 HU or greater between pre- and postcontrast phases [17]. The exact change considered to be positive for enhancement has not been
universally agreed upon for helical CT, and may also vary depending on acquisition parameters,
including position within the FOV and the calibration of the CT scanner used [18].
1.2.1 Renal Cell Carcinoma
Renal cell carcinoma (RCC) is the most common kidney cancer in adults, accounting for
approximately 90% of renal neoplasms and 3% of all adult malignancies, and resulted in
approximately 14,00 deaths in 2014 [19]. RCC is an aggressive disease that forms in the lining of
the proximal tubular epithelium, and has a 5-year survival rate of 95% for stage 1 disease, but less
than 20% for state 4 disease [20].
The diagnosis of RCC based on the appearance of the lesion on CT imaging can vary
widely in difficulty. Diagnosis of a simple, non-enhancing cyst is straightforward while
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classifying complex lesions is much more challenging [15]. In an effort to standardize the
classification and management of renal lesions, the Bosniak Classification system was proposed
in 1986 [16] and was updated in 2005 [16, 21]. A simplified description of the four classifications
for renal lesions according to the Bosniak system is given in Table 1 [21].
Category Description
I

A benign simple cyst that uniformly measures water density and does not enhance

II

A benign cyst that may contain a few hairline thin septa in which “perceived” (not
measureable) enhancement may be present. Cysts in this category do not require
further evaluation.

IIF

A cyst that may contain multiple hairline thin septa and “perceived” enhancement
may be present. Calcification may be present, but there is no measurable
enhancement. Cysts in this category require further evaluation to prove benignity.

III

“Intermediate” cystic masses in which measurable enhancement is present. These
are surgical lesions that may prove to be benign or malignant, such as RCC

IV

Clearly malignant cystic masses that meet criteria III and additionally contain
enhancing soft-tissue adjacent to the wall or septum. These include cystic
carcinomas and require surgical removal.
Table 1. Bosniak renal cyst classification system [21]

During a typical multiphase renal CT exam a patient undergoes an unenhanced scan,
followed by intravenous administration of a contrast agent and several post-contrast scans, some
of which may be delayed by several minutes to evaluate washout of the contrast. Studies have
shown that if the patient has an enhancing renal mass, such as RCC, the mass will have a
substantial non-calcified region with a CT number measuring within a range of 20-70 HU on
unenhanced CT, while normal renal parenchyma will measure approximately 30 HU [22]. In a
post-contrast scan acquired during the corticomedullary phase, studies have shown that RCC will
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enhance significantly more than a benign cyst (112.9 HU vs 59.8 HU, respectively [23]) and that
a difference of greater than 42 HU in the measured enhancement during the corticomedullary
phase from the unenhanced phase was highly predictive of RCC [23]. During the
corticomedullary phase, normal renal parenchyma will measure approximately 200-300 HU,
which is greater than the typical post-contrast CT number of an RCC mass.
Imaging in the post-contrast phase may not allow for distinct differentiation of
hyperattenuating cysts from renal neoplasms. Acquiring a delayed phase can demonstrate contrast
washout, or de-enhancement, associated with a diagnosis of vascularity of the mass, allowing for
differentiation of hyperattenuating cysts from renal neoplasms [24].
1.2.2 Angiomyolipoma
Accurate classification of renal masses is essential to prevent unnecessary medical
intervention. As previously discussed, RCC is a dangerous disease and should be completely
resected from the kidney when present. But there are some masses, commonly referred to as
pseudotumors, which can mimic RCC on unenhanced CT scans. An example of a pseudotumor is
angiomyolipoma (AML), which is the most common benign tumor of the kidney [25]. AML is
commonly diagnosed by the detection of fat and the measurement of CT numbers on unenhanced
CT scans. However, in approximately 4.5% of cases the mass is “lipid-poor” and no fat can be
visualized on CT [26]. In these cases, AML is commonly suspected as being RCC and is treated
unnecessarily. Thus, the ability of an unenhanced CT image to accurately reflect fatty
characteristics of a mass is crucial.
1.3 Virtual Unenhanced Imaging
The material decomposition capability provided by DECT allows for the estimation of
the amounts of two basis materials contained within each voxel of an image. An example of such
a material basis pair is water and iodine. Virtual Unenhanced (VUE) imaging extends basis
material decomposition to create a virtual pre-contrast CT dataset from a DECT acquisition.
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Conceptually, basis pair material decomposition is performed into water and iodine projections,
and then the calculated iodine concentration is removed and replaced with a suitable material
[27]. In the VUE implementation, the material suppressed iodine (MSI) algorithm (General
Electric Healthcare, Milwaukee, WI) estimates the volume of iodine contrast contained within
each voxel and replaces it with an equivalent volume of blood, which is the material that iodine
contrast has likely displaced in a post-contrast CT acquisition [27]. While this technique can be
generalized to decompose an image into an arbitrary number of materials [10], the technique
employed in VUE image reconstruction is believed to utilize a two-material decomposition
technique [7].
This algorithm is based on a model that assumes the materials within each voxel mix to
form an ideal solution, i.e., the volume of a mixture equals the sum of the volumes of the
constituent materials [27]. Using this model, the linear attenuation coefficient for each voxel in
the VUE image at a given energy can be described mathematically as [27]:
µ(𝐸) = ∑𝑁
𝑖=1 𝛼𝑖 𝜇𝑖 (𝐸)

Equation 1.3-1

where
𝑣

𝛼𝑖 = ∑ 𝑣𝑖

𝑗

∑𝑁
𝑖=1 𝛼𝑖 = 1

϶

Equation 1.3-2

Since the materials in each voxel mix to form an ideal solution, the sum of the volume of contrast
and the volume of blood in a mixture of contrast and blood would equal the volume of the total
mixture. Based on the assumption that iodine displaces only blood, the volume of blood in the
VUE image would be set equal to the volume of contrast in the post-contrast image. Therefore,
the volume of contrast removed from each voxel is replaced with the equivalent volume of blood.
Since the development of the virtual unenhanced imaging reconstruction technique, many
potential applications have been investigated. Such applications include:
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Replacement of pre-contrast images with virtual non-contrast images in
o

Renal DECT exams, the feasibility of which is the focus of this work
[3, 7, 9, 28]





o

Liver DECT exams [29, 30]

o

DECT urography for detecting urinary stones [31, 32]

o

DECT cholangiography [33]

Utilizing a virtual noncalcium technique in:
o

Detection of posttraumatic bone marrow lesions [34]

o

Detection of bone marrow edema in acute fractures [35]

Radiotherapy treatment planning to improve dose calculations [36]

A prior study has compared a number of patient CT datasets using both true pre-contrast and
virtual non-contrast datasets in multiphase renal exams with a dual-source DECT technique and
has shown promising results [9]; however, a careful systematic evaluation of this technique has
not been completed which is the focus of this work. This study also evaluats a different DECT
acquisition technique and reconstruction algorithm for generating virtual non-contrast datasets.
Some prior studies are based on a three-material decomposition algorithm used for VUE image
reconstruction, whereas this study will focus on a two-material decomposition algorithm [7, 9].
1.4 Motivation
There are several potential benefits to be realized from replacing true unenhanced (TUE)
images with virtual unenhanced (VUE) images during multiphase renal CT exams. The first, and
perhaps most significant, is the reduction in patient radiation dose. Previous studies have
demonstrated that reductions in radiation dose can be as great as 35% [9]. Second, eliminating the
pre-contrast phase would reduce the exam time for each patient and consequently could increase
patient throughput and clinical efficiency. Finally because VUE images are reconstructed from
post-contrast images, a pre-contrast scan would no longer need to be registered to the post12

contrast scans, which would potentially reduce misregistration and differences in partial volume
averaging between the pre- and post-contrast scans [37].
These potential benefits motivated this study, which assessed the feasibility of replacing
TUE images with VUE images reconstructed from post-contrast images acquired using DECT.
As previously discussed, characterization of renal masses is a complicated and sometimes
equivocal process, and therefore the quality of VUE images must be carefully assessed to ensure
that diagnostic quality is maintained.

13

Chapter 2. Hypothesis
2.1 Statement of Hypothesis
Classification and quantitative evaluation of renal lesions is not significantly different when using
virtual unenhanced images (VUE) in place of true unenhanced images (TUE) based on a p-value
of 0.05. Additionally, classification of images based on enhancement measurements will not be
different when using VUE images versus TUE images for the baseline measurement across a
wide range of clinical scenarios based on a posterior probability of 0.05 for negative significance
and 0.95 for positive significance using a mixed effects model.
2.2 Research Approach
In order to test this hypothesis, the project was divided into three specific aims. Each aim
contributed to testing the stated hypothesis.
Specific Aim 1: A retrospective study of 60 patient exams was conducted for qualitative and
quantitative evaluation of VUE and TUE images.


Sub aim 1.1: Three radiologists were presented with VUE and TUE images for
qualitative evaluation. The results were analyzed with a Bayesian Hierarchical
model to determine if VUE images were significantly different from TUE images.



Sub aim 1.2: VUE images were compared to TUE images by using quantitative
measurements of specific regions of interest in each of the 60 unique patient exams.
These regions of interest included liver, aorta, spleen, spine, cystic lesions (if
present), subcutaneous fat, and the renal cortex and medulla. The results were
compared using a paired t-test.

Specific Aim 2: Characterization of lesions using VUE images compared to TUE images
was assessed using a set of three patient-mimicking phantoms. These phantoms were used to
acquire an extensive data-set for the comparison of lesion characterization in each under
varying conditions.
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Sub aim 2.1: Three phantoms were constructed specifically for this research project
to represent patients of small, medium, and large sizes.



Sub aim 2.2: The medium phantom was used to acquire images with a fixed
configuration (i.e., one lesion size in a specific position in the SFOV) and variation
only in the GSI protocol used. The acquired images were evaluated to determine up
to five candidate GSI protocols that were to be used for evaluation of the medium
and small phantoms. This same process was repeated to determine candidate GSI
protocols for evaluation of the large phantom.



Sub aim 2.3: All phantoms were imaged in different configurations using the GSI
protocols identified in Sub aim 2.2. The variables in configuration setup included
location of the lesion within the SFOV, lesion size, phantom size, image thickness,
contrast concentration, and selected GSI protocol. The results were analyzed using a
Bayesian Hierarchical model.



Sub aim 2.4: A set of up to 3 optimal clinical GSI protocols will be identified and
recommended for clinical use in clinical multiphase DECT for renal evaluation, if
differing from current clinically used protocols.

Specific Aim 3: The effect of ASIR (adaptive statistical iterative reconstruction) on VUE CT
number measurements was evaluated.


Sub Aim 3.1: A subset of images acquired in Sum Aim 2.3 were used to reconstruct
VUE images with varying levels of ASIR under varying conditions. The variables in
configuration setup included location of the lesion within the SFOV, lesion size,
phantom size, image thickness, contrast concentration, and selected GSI protocol.
The variation in reconstruction technique involved application of 0%, 60%, and
100% ASIR levels for each phantom configuration. The results were analyzed using
a mixed effects model.
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Chapter 3. Methodology
3.1

Specific Aim 1 Methods
Virtual unenhanced images were reconstructed from DECT data sets for 60 consecutive

patient exams using version 2.0 of the GE AW Server. A single source multi-detector row GE
Discovery CT750HD (General Electric Healthcare, Milwaukee, WI) scanner was used to acquire
the patient exams, an example of which is shown in Figure 2. This system consisted of one X-ray
tube which rapidly switched between two energy spectra and a corresponding 64-channel detector
with 0.625 mm channel width. The DECT data set was then loaded onto the dedicated DECT
post-processing workstation (AW Server, version 2.0; General Electric Healthcare) for
reconstruction. The multi-material decomposition algorithm, referred to as Material Suppressed
Iodine (MSI), was then applied to post-contrast images in the GSI Volume Viewer (General
Electric Healthcare, Milwaukee, WI), to reconstruct the VUE images. Each image was
reconstructed at 3.75 mm thickness, 2.5 mm interval, and a DFOV identical to that used to
acquire the TUE. VUE images were reconstructed for all 60 patient cases, for a total of 120
images (60 VUE and 60 TUE) for analysis.

Figure 2. GE Discovery CT750HD Scanner
60 standard of care patient examinations with an indication of pancreatic lesions were
consecutively selected for retrospective analysis. The demographics of the patients examined are
given in Table 2.
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N

Mean age (yrs)

Age range (yrs)

Mean BMI (kg/m2)

Male

33

63

39 - 77

25.7

Female

27

60

33 - 79

27.1

Total

60

62

33 - 79

26.3

Table 2. Demographic Information for Patients used in Retrospective Study
An unenhanced scan of each patient was first acquired using 120 kVp with tube current
modulation, a pitch of 0.984, and a gantry rotation time of 0.8 s. The iodine contrast agent was
administered intravenously at an injection rate of 4cc/sec (125 cc total) with a delay of 40 seconds
and a DECT dataset was acquired during the arterial phase. A pitch of either 0.516 or 0.984 was
used with a corresponding gantry rotation time of 0.5 s or 0.8 s, respectively. The DECT dataset
was acquired using beam energies of 80 kVp and 140 kVp. The interleaved high and low
projections were used to generate water and iodine attenuation maps, which were then used for
VUE image reconstruction.
The patient cases used for Specific Aim 1 were standard of care, and were analyzed
retrospectively. As a consequence the raw data were not available for image reconstruction;
therefore it was not possible to exactly match reconstruction parameters between TUE and VUE
images. This was problematic in particular because different reconstruction kernels and different
levels of iterative reconstruction (Adaptive Statistical Iterative Reconstruction [ASIR], General
Electric Healthcare) were applied to the TUE images and the DECT dataset. TUE images were
reconstructed with the SOFT kernel and 60% ASIR, whereas the VUE images were reconstructed
with the STANDARD kernel and 0% ASIR. This variation in reconstruction is a limitation of the
study, as it may have affected the qualitative comparison of VUE to TUE images.

17

3.1.1 Sub aim 1.1
A qualitative comparison of VUE and TUE images was conducted with three experienced
radiologists. Images were blinded as to method of reconstruction and presented to each
radiologist individually. Each radiologist was asked to complete a questionnaire for each image
presented. The full survey presented with the associated instructions are provided in Appendix
6.1. The survey evaluated the following image characteristics using a Likert scale:
1. Visualization of major vessels (considering hepatic, portal, and renal veins in particular)
2. Visually sharp reproduction of the pancreatic contour
3. Visualization of calcifications
4. Depiction of liver parenchyma, e.g., ability to determination of the degree of fatty
infiltration
5. Visualization of adrenal glands
6. Corticomedullary differentiation
A random subset of 15 patient cases was selected to be repeated to quantify intra-observer
variability. The complete set of images presented to each radiologist included 150 images in total
(60 VUE and 60 TUE unique images, as well as 15 repeated VUE images and the corresponding
15 repeated TUE images). Each radiologist completed the retrospective evaluation in multiple
sessions to minimize fatigue. The data from this study were analyzed using a Bayesian
Hierarchical model.
3.1.2 Sub aim 1.2
A quantitative comparison of the TUE and VUE images was conducted using the version
2.0 of the GE AW Server. Each TUE image was non-rigidly registered to the corresponding VUE
image prior to ROI placement using the “Integrated Registration” feature of the post-processing
workstation. ROI measurements were made in the following anatomical regions in all images:
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Liver



Abdominal aorta



Inferior vena cava



Spleen



Spine



Renal medulla



Renal cortex



Cystic lesion (if present)



Subcutaneous fat

Notice that the selected regions were anatomically different, comprising tissues of differing
density and attenuation properties for analysis of the impact of the MSI algorithm on tissues with
varying amounts of iodine contrast on board. Theoretically the spine and subcutaneous fat should
be minimally affected by the MSI algorithm because these regions generally do not uptake iodine
contrast.
Regions of interest placed in each tissue ranged in area from 30 mm 2 to 700 mm2,
depending on the size of the anatomical structure. Examples of ROI placement are shown in
Figure 3. The data from this study were analyzed using a student’s paired t-test.

Figure 3. Example ROI placement for quantitative measurements, from left to right: (left
image) liver, spine, spleen; (center image) renal cortex, renal medulla, abdominal aorta,
subcutaneous fat; (right image) cystic lesion
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3.2 Specific Aim 2 Methods
A phantom study was conducted to assess the accuracy of lesion characterization when
using VUE images in place of TUE images. Phantoms were constructed at the MD Anderson
Center for Advanced Biomedical Imaging (CABI) machine shop. The phantoms were used to
acquire an extensive data-set for lesion characterization across varying conditions. The GE
Discovery CT750HD DECT scanner with Gemstone Spectral Imaging (GSI) capability located at
CABI was used for all data acquisition and the GE AW workstation was used for all image
processing.

3.2.1 Sub aim 2.1
Three phantoms were constructed to represent patients of small, medium, and large sizes.
Each phantom contained the following:


Delrin rod 3.67 cm in diameter to mimic patient spine



Insert for PMMA hollow sphere 1.0 cm in diameter located to the right of the spine



Insert for 3 PMMA hollow spheres of diameter 1.0, 2.0, and 3.0 cm located in the
periphery of the phantom. The three different size inserts allowed for assessment of
variation of lesion size on enhancement accuracy. Additionally, the 1.0 cm sphere was
compared to the 1.0 cm sphere located in the right kidney region for evaluation of the
effect of lesion position within the field of view (FOV) enhancement accuracy.



Insert for PMMA cylinder 1.0 cm in diameter located to the left of the spine

The distance of each insert from the Delrin rod (spine) varied depending on patient size. All
phantoms were composed of four elliptical plates that were 5 cm thick, yielding a total length of
20 cm for all phantoms. An axial section of the design for each phantom, including the distance
of each insert from the Delrin rod, is given in Appendix 6.2.
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Phantom Dimensions (cm)
Phantom Size

Major
Axis

Minor
Axis

Small

28.3

17.4

Medium

36.1

22.2

Large

47.9

29.4

Table 3. Phantom Dimensions
The dimensions of each phantom are displayed in Table 3 and were based on the 5th
(small), 50th (medium), and 95th (large) percentiles of the United States population from the
People-Size 2008 visual anthropometry software (Open Ergonomics Ltd, Leicestershire, UK). An
example CT image of the medium phantom with the 3 cm outer sphere, 1 cm inner sphere, and 1
cm rod insert in place is included in Table 3. Each phantom was composed of four 5 cm thick
high density polyethylene (HDPE) elliptical plates. Three sets of the two central plates for each
phantom were constructed to accommodate the 1, 2, and 3 cm outer spherical inserts, which
simulated variation in lesion size, pictured in Figure 4.

Figure 4. The three sets of exchangeable phantom plates for the small phantom, which
accommodated spherical lesions of varying diameter. Each set served as the center two
plates of the phantom, and could be exchanged to allow for different lesion sizes
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Figure 5. Custom designed small phantom fully assembled (left image), the center two plates
(center image), and half assembled (right image)
3.2.2 Technical Notes
3.2.2.1 Relationship between CT number and iodine concentration
For phantom experimentation, a relationship between CT number and iodine
concentration was determined. Variation in energy spectra across CT scanners makes analytic
calculation of this relationship difficult; therefore it was determined experimentally. Previous
experiments had shown that for a 120 kVp beam the relationship between iodine concentration
and CT number can be expressed as [38]:
𝑚𝑔
𝐼𝑜𝑑𝑖𝑛𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 ( ⁄𝑚𝐿) = 0.0365 ∗ (𝐶𝑇 𝑛𝑢𝑚𝑏𝑒𝑟) − 0.85

Equation 3.2.2.1-1

Using this relationship as a baseline for developing the methodology for this experiment,
six Optiray 320 (Mallinckrodt Pharmaceuticals, St. Louis, MO) and water mixtures were chosen,
as given in Table 4. The medium phantom with the 3 cm diameter insert, which had a volume of
14.1 mL, was used for each trial. The iodine concentration for each mixture was calculated using
the volume of the insert, as well as the concentration of Optiray 320, which contained 320 mg/mL
organically bound iodine. The volume of Optiray 320 was measured using a 2 mL volumetric
pipette, which had a reported uncertainty of ± 0.01 mL. Images were acquired with the GE
HD750 DECT scanner using the GSI-37 DECT protocol (medium body filter, 0.8 sec rotation
time, 40 mm beam width, 0.984 pitch, 260 mA, and a CTDIvol of 10.99 mGy) and a 2.5 mm
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image thickness. For each trial, the mean CT number (HU) and standard deviation were recorded
from a circular region of interest (ROI) of approximately 150 mm2 drawn in the center of the 3 cm
sphere in the central axial image through the sphere. The ROI was propagated through the two
images superior and inferior to the central image for a total of five ROI measurements on
consecutive slices. The average of these measurements was computed and linear regression was
used to calculate the relationship between CT number (HU) and iodine concentration (mg/mL)
for the CT scanner used in this study.

Trial

Optiray (mL)

Concentration
of Optiray by
volume (%)

Concentration
of Water by
volume (%)

Iodine
Concentration
(mg/mL)

1

0.14

0.99

99.01

3.17

2

0.28

1.98

98.02

6.34

3

0.42

2.97

97.03

9.51

4

0.56

3.96

96.04

12.68

5

0.70

4.95

95.05

15.84

6

0.84

5.94

94.06

19.01

Table 4. Iodine concentrations used for experimentation

3.2.2.2 Phantom set-up verification
As discussed in section 1.2.1, renal cell carcinoma (RCC) has been shown to enhance
from the range of 20-70 HU in the pre-contrast image to approximately 110 HU in the
corticomedullary phase [22, 23], while normal kidney parenchyma enhances from approximately
30 HU to 200-300 HU. As a result, in an actual patient exam TUE images will be obtained when
the renal mass has an attenuation approximately equal to or greater than the surrounding renal
tissue, and VUE images are reconstructed from DECT data acquired when the renal mass has
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attenuation less than that of the surrounding normal tissue. In practice, the DECT image is
acquired with the renal mass in a positive enhancing background, whereas with the phantom
constructed for this study simulated renal masses in a negative contrast background. The potential
impact of the differences between clinical CT and the phantom study was evaluated using the
Jaszczak Phantom (Biodex, Shirley New York) imaged in two configurations, one mimicking the
expected patient scenario and the other mimicking the phantom scenario, the details of which are
given in Table 5. The Jaszczak phantom was configured with three hollow spheres of different
sizes (Table 5 and Figure 6). The relationship between CT number and iodine concentration
determined experimentally (section 4.2.1.1) was used to calculate the amount of iodine contrast
necessary to achieve the desired CT number.
Sphere

Background

Experiment 1:
Patient set-up

Iodine-water
mixture (100 HU)

Iodine-water
mixture (250 HU)

Experiment 2:
Phantom set-up

Iodine-water
mixture (100 HU)

Water (0 HU)

Table 5. Jaszczak Phantom Experiment

Figure 6. Example images from the Jaszczak phantom experiment. An expected patient
scenario for post-contrast imaging in the corticomedullary phase was simulated (left), as
well as the phantom set-up (right)
DECT Images were acquired with the GE HD750 scanner using the GSI-11 DECT
protocol (medium body filter, 36 cm DFOV, 0.8 sec rotation time, 40 mm beam width, 600 mA,
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0.984 pitch, and a CTDIvol of 26.70 mGy) and a 2.5 mm image thickness. VUE images were
reconstructed from all DECT images. For each experiment, the mean CT number (HU) and
standard deviation were recorded from a circular region of interest (ROI) of approximately 150
mm2 for the 31.8 mm diameter sphere and 100 mm2 for the 25.4 mm diameter sphere drawn in the
central axial image through the sphere. The ROI was propagated through the two images
immediately superior and inferior to the central image to yield ROI measurements on five
consecutive images.

3.2.3 Sub aim 2.2
A single configuration was selected for imaging the medium phantom, so as to bridge the
retrospective study to the phantom study. The parameters selected were informed by techniques
used to acquire the unenhanced and DECT images in the retrospective study, and are listed in
Table 6. All available GSI protocols on the GE CT750HD scanner for the medium size bowtie
were used for image acquisition. A complete list of the presets used is given in Appendix 6.3.
Medium

Medium

Phantom (DECT)

Phantom (TUE)

Image thickness

5.0 mm

5.0 mm

DFOV

400

400

Pitch

0.984

0.984

kVp, mAs

GSI protocol dependent

120, 150

Lesion diameter

3 cm

3 cm

Parameter

Table 6. Imaging parameters for the single phantom configuration used for comparison of
GSI protocols
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The phantom inserts were filled with an Optiray 320 and water mixture with 3.38 mg/mL
iodine concentration to simulate approximately 80 HU enhancement for DECT image acquisition,
and with water only for TUE image acquisition. The following equation was used to convert the
calculated iodine concentration necessary to simulate a given CT number to Optiray 320
concentration:
𝑶𝒑𝒕𝒊𝒓𝒂𝒚 (𝒎𝑳) =

𝒊𝒐𝒅𝒊𝒏𝒆 (𝒎𝒈⁄𝒎𝑳)∗𝒕𝒐𝒕𝒂𝒍 𝒗𝒐𝒍𝒖𝒎𝒆 (𝒎𝑳)
𝟑𝟐𝟎 (𝒎𝒈/𝒎𝑳)

Equation 3.2.3-1

VUE images were reconstructed from DECT images and compared to TUE images acquired with
water only in the inserts. The intention of this experiment was to determine which GSI protocol
produced VUE images in which measured CT numbers most closely matched those in TUE
images, and then to use this information to identify 3-5 candidate protocols for further evaluation.
CT numbers and their associated standard deviations were measured from a circular ROI placed
in the center of each insert as well as in the spine of the phantom for VUE and TUE images. The
dimensions of the ROIs placed for each image are given in Table 7.
ROI size (mm2)

ROI Location
Center insert
Peripheral
insert

14.4
1 cm

14.4

2 cm

70-80

3 cm

140-150

Hollow rod insert

6.0

Delrin rod

320-350

Table 7. Dimensions of ROI placement for each measurement location in TUE and VUE
images
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3.2.4 Sub aim 2.3
Phantoms were imaged in different configurations using the GSI protocols identified in
Sub Aim 2.2, which are listed in section 4.2.2. The following parameters were varied to assess the
effect of patient specific factors on the accuracy of enhancement measurements assessed using
DECT:


Patient size: As discussed previously, variation in patient size was evaluated by imaging
three phantoms of different sizes. The dimensions of each phantom are listed in Table 3.



Lesion size: Hollow spheres of 1 cm, 2 cm, and 3 cm diameter were used to simulate
variation in lesion size.

Figure 7. Variation in lesion size for the small phantom


Position within the field of view (FOV): Each phantom also contained a 1 cm hollow
sphere near the spine insert in addition to the 1 cm sphere mentioned in the previous
section, which was located in the periphery of the phantom. These spheres were used to
study the effect of position within the FOV on enhancement accuracy. The distance of
each lesion from the Delrin rod increased proportionally with increasing phantom size.

“Periphery”
“Center”

Figure 8. Variation of position of the lesion within the FOV
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GSI protocol: As determined in Sub Aim 2.2, GSI protocols 10, 11, 16, and 29 were used
for the small and medium phantoms and GSI protocols 10, 12, 22, 36 were used for the
large phantom to study the impact of GSI protocol on quantitative accuracy of DECT.
The parameters associated with each of these protocols are listed in Table 19.



Enhancement magnitude: The purpose of varying contrast concentration was to assess
VUE enhancement accuracy across a wide range of simulated clinical scenarios. The
clinical scenarios used to vary iodine concentration are detailed in the following sections.

The most common method for classifying renal lesions is the Bosniak criteria [19]. These
guidelines provide a method for categorizing cystic lesions based on several characteristics
including enhancement of the lesion, which has been stated to be the most important criterion
used in determining surgical from non-surgical renal masses [17]. Consequently, it is crucial that
CT numbers measured in pre- and post-contrast images are accurate. This motivated the
incorporation of variation in iodine concentration as a parameter of interest in the phantom study.
Five clinical scenarios were simulated, each of which are detailed in the following sections.
For each simulation, the concentration of Optiray 320 necessary was determined using
the relationship between CT number and iodine concentration given in 4.2.1.1. Optiray 320 was
measured for each solution using a 2 mL volumetric pipette with an associated uncertainty of ±
0.01 mL. Images were then acquired using the GE HD750 DECT scanner. VUE images were
reconstructed from DECT data and then CT number, as well as the associated standard deviation
of the measurement, was recorded from ROI placement in various regions of the phantom. The
dimensions of the ROIs for each measurement location are listed in Table 7. The data were
analyzed using a mixed effects model that accounted for both fixed and random effects, which is
further discussed in 4.2.4. In Clinical Scenarios 1 and 2, VUE images were reconstructed from
DECT images and were compared to TUE images acquired using SECT. A conceptual
explanation of the experimental design for Clinical Scenarios 3-5 is given in Table 8. Further
explanation regarding the solutions used to simulate each scenario is detailed in the following
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sections. An example of the image acquisition matrices for SECT images and for DECT is
provided in Appendix 6.4.
Pre-contrast
TUE
(SECT)

Acquired as
“baseline” with
no Optiray 320

Reconstruction
VUE
from DECT post(DECT)
contrast images

Post-contrast

Analysis

SECT

Acquired with the
specified concentration
of Optiray 320

Enhancement =
SECT – TUE

DECT

Acquired with the
specified concentration
of Optiray 320

Enhancement =
DECT – VUE

Table 8. Conceptual description of the experiment design for Scenarios 3-5
Scenario 1
A fatty lesion was simulated to mimic angiomyolipoma (AML), which is a non-surgical
renal pseudotumor that can mimic a mass requiring surgery, such as renal cell carcinoma. This
simulation allowed for assessment of the ability of VUE images to accurately represent fatty
lesions. As discussed in section 1.2.2, this simulation represented a clinical scenario in which it is
crucial to distinguish AML from RCC to avoid unnecessary intervention.
The AML lesions were simulated by filling the inserts for the phantom with vegetable oil,
yielding a CT number of approximately -100 HU. All images were acquired with only vegetable
oil in the spheres.

Figure 9. TUE (left) and VUE (right) of small phantom for Scenario 1
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Scenario 2
This scenario, along with those to follow, served to simulate the categories of the Bosniak
criteria, which are detailed in Table 1. Category I of the Bosniak criteria describes a benign
simple cyst that measures water density and does not enhance [21]. Simple benign cysts were
simulated by filling the phantom inserts with distilled water. All images were acquired with only
distilled water in the spheres.

Figure 10. TUE (left) and VUE (right) of small phantom for Scenario 2
Scenario 3
Category II-IIF of the Bosniak criteria describes a benign cyst in which enhancement
may be perceived, and those in category IIF require follow-up studies to prove benignity [21]. In
order to simulate a lesion that is likely benign, but requires further investigation to prove
benignity, such as a category IIF cyst, a baseline attenuation of 20 HU was simulated to represent
the pre-contrast phase of imaging. A 20 HU baseline was chosen because it represented a
borderline measurement for identification of RCC on a TUE image, which typically measures in
the 20-70 HU “danger zone” in the pre-contrast imaging phase [22]. For post-contrast simulation,
Optiray 320 was added to the solution to simulate a small amount of enhancement. For a lesion in
this category, enhancement may be perceived but would be minimal [21]. As discussed in section
1.2, it was previously believed that 10 HU was the threshold for enhancement determination, but
with the advent of helical CT it was proposed that this threshold be increased to 15 or even 20
HU, and there is currently no universal agreement on this matter [16, 17]. Considering this, two
enhancement scenarios were simulated for this experiment to represent a low “perceived”
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enhancement of 5-10 HU and a borderline, or intermediate, enhancement of approximately15-20
HU.
The baseline images for this scenario were acquired with an apple juice and water
mixture to simulate an attenuation of 20 HU. Apple juice was chosen for simulation in this and
the subsequent scenarios as a surrogate for blood because it has an effective atomic number,
density, and CT number that is very similar to blood. Optiray 320 was then added to the mixture
to simulate each enhancement scenario, and the SECT and DECT post-contrast images were
acquired. The Optiray 320 concentrations necessary to simulate these levels of enhancement were
calculated based on the relationship determined in section 4.2.1.

Figure 11. TUE (left) and VUE (right) of small phantoms for Scenario 3, VUE image
pictured was reconstructed from the intermediate enhancement DECT image
Scenario 4
A Bosniak Category III lesion is intermediate that requires further work-up, for example
a lesion measuring approximately 40 HU on a pre-contrast image and exhibiting slight
enhancement in post contrast images. An attenuation of 40 HU was chosen for this scenario as
well as for Scenario 5 because a recent study has shown that the attenuation of renal neoplasms as
measured by a radiologist was on average 38.4 HU [39]. Two enhancement scenarios were
simulated to represent low enhancement (5-10 HU) and intermediate enhancement (15-20 HU).
As previously stated, the aim of scenarios 3-4 was to simulate borderline lesions for comparison
of TUE to VUE as the baseline image for enhancement measurements, which is where the
accuracy of an enhancement calculation is the most crucial.
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The baseline SECT images were acquired with an apple juice/water mixture (with a CT
number of approximately 40 HU) in the inserts and the DECT images were acquired with Optiray
320 added to the mixture, as described previously.

Figure 12. TUE (left) and VUE (right) of small phantom for Scenario 4, VUE image
pictured was reconstructed from the low enhancement DECT image
Scenario 5
Bosniak Category IV describes a lesion that is clearly malignant and enhances substantially
[21]. A lesion in this category will exhibit high vascularity and consequently demonstrate
substantial uptake of iodine contrast in post-contrast imaging, resulting in significant
enhancement. An enhancement of approximately 40-50 HU was chosen for simulation because it
demonstrates definitive enhancement and is in the range of typical enhancement of RCC. A
previous study has shown that clear cell renal carcinoma (cRCC) and papillary renal cell
carcinoma (pRCC) enhance to a mean of 149 and 91 HU, respectively, in the corticomedullary
phase and 95 and 71 HU, respectively, in the nephrographic phase [40].
This was simulated by using apple juice/water mixture for the baseline unenhanced image.
Optiray 320 contrast was then added to the mixture to result in a total attenuation of 80 HU,
which corresponded to an enhancement of 40 HU.

Figure 13. TUE (left) and VUE (right) of small phantoms for Scenario 5
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For each scenario, CT number and image noise were measured in all inserts. The data
collected were analyzed using a mixed effects model, chosen to account for fixed and random
effects in the study. The details of this model are given in section 4.2.4. A summary of the five
clinical scenarios simulated is given in Table 9.
Clinical Scenario

TUE baseline (HU)

Enhancement (HU)

Purpose:

Fatty lesion

-100

None

Ability to distinguish
fatty lesions

Bosniak I

0

None

Ability to distinguish
a benign simple cyst

Bosniak II-IIF

20

5-10, 15-20

Bosniak III

40

5-10, 15-20

Bosniak IV

40

40-50

Assess lesion
enhancement accuracy

Table 9. Summary of clinical scenarios for experiments

An evaluation of the sources of variation in the measurements was necessary to account
for random effects in the mixed effects model. The potential sources of random error were
identified as preparation of the solutions and phantom set-up (σP), scanner variability (σS),
variation between images in each acquisition (σM), and variation across the ROI, or quantum
noise (σN).
Variation in preparation of the solutions (σP) was controlled for in the design of the
experiments. For each prepared solution all images needed for all phantom configurations for that
particular solution were acquired using a single preparation of inserts. That is, one mixture was
created and used for all imaging; therefore limiting uncertainty due to systematic error, which
was associated with the use of a volumetric pipette to measure the Optiray 320 concentrations,
which had a reported uncertainty of ± 0.01 mL.
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The random error of the CABI CT scanner (σS) was evaluated by using the QC data
collected daily on the scanner over the course of two months. This analysis only considered the
CABI CT 750HD scanner because it was the only scanner used for image acquisition in these
experiments. The mean of the CT number measurements recorded for water each day was
calculated, as well as the associated standard deviation. The standard deviation was then used to
calculate the standard error (σS).
Variation between ROI measurement locations within the simulated lesion (σM) was
considered as a source of random error. This was quantified by randomly selecting images from
the experiment, and repeating CT number measurements 10 times in each region of interest. The
standard deviation of the mean was computed, and then used to calculate the standard error. The
standard error was < 0.1 in all cases, and was therefore considered to be negligible. This
conclusion is expected considering the size of the ROI placed relative to the diameter of the
spherical inserts constrained variation. Note that image-to-image variation was not considered
because of the size of the spherical inserts relative to the 5.0 mm thickness of the images. Given
that measurements were made in the 1 cm sphere for all images, there was only one image in each
case where measurements could be made with minimal partial volume effect.
The SE associated with quantum noise (σN) was quantified by calculating the standard
error of the mean CT number. For Scenarios 1 and 2, this was done using the recorded the
standard deviation of each ROI measurement and the calculated number of pixels in each ROI.
This could not be done for Scenarios 3, 4, and 5 because the result used for analysis was the
difference between pre- and post- contrast measurements, i.e. the enhancement value. Notice that
a standard deviation was recorded for each pre- and post-contrast measurement. In order to
determine σN for these scenarios, the standard error was calculated for each pre- and post-contrast
measurement and the results were added in quadrature [41]:
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𝟐

𝟐

𝝈𝑵 = √(𝝈𝒑𝒓𝒆 ) + (𝝈𝒑𝒐𝒔𝒕 )

Equation 3.2.4-1

The total variation was then calculated by adding each source of variation in quadrature
for each measurement. The estimated variation used as the input for random error in the mixed
effects model is shown in equation 3.2.4-2.
𝝈𝒕𝒐𝒕𝒂𝒍 = √(𝝈𝑺 )𝟐 + (𝝈𝑵 )𝟐

Equation 3.2.4-2

3.2.5 Sub aim 2.4
The purpose of this sub aim was to determine a set of up to three optimal GSI protocols
to recommend for clinical DECT image acquisition, which could be used to reconstruct VUE
images. This was not done because the results of this study do not support the clinical
replacement of TUE images with VUE images.

35

3.4 Specific Aim 3 Methods
An evaluation of the effect of ASIR (adaptive statistical iterative reconstruction) on CT
number accuracy of the VUE images was conducted. ASIR is a form of iterative reconstruction
that begins after a first pass of filtered back projection reconstruction is completed, which
shortens the time of reconstruction as compared to purely iterative techniques. The potential
benefit driving clinicians to use ASIR is the reduction in noise, which could allow for reduction
in the mA required to maintain diagnostic image quality, and consequently a reduction in patient
dose.
A subset of the images acquired in Sub Aim 2.3 was used for this experiment to assess
the impact of ASIR levels under varying phantom configurations. The variables selected to be
assessed for this experiment were informed by observations made from Sub Aim 2.3 data. For
each phantom configuration used, images were reconstructed with 0%, 60%, and 100% ASIR
levels. The variables considered for this experiment were:
•

Patient size: small, medium, and large

•

Lesion size: 1 cm and 3 cm

•

GSI protocol: the same protocols used in Sub Aim 2.3 will be assessed in this
experiment

•

Contrast concentration: 20 HU baseline lesion with 15-20 HU enhancement and 40
HU baseline lesion with 40 HU enhancement

•

ASIR level: 0%, 60%, 100%

For each image set acquired CT number and noise were measured on the GE AW workstation in
the spherical inserts as well as the Delrin rod, which mimics spine. The dimensions of the ROIs
drawn for measurements are given in Table 7. Results were analyzed using a mixed effects
model, the details of which are given in section 4.2.4.
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Chapter 4. Results
4.1 Specific Aim 1
A retrospective analysis of 60 patient cases, with quantitative and qualitative
comparisons, was conducted to statistically test the feasibility of replacing TUE with VUE
images.
4.1.1 Results: Sub Aim 1.1
The qualitative study was based on a questionnaire given independently to three
experienced radiologists for a total of 150 images (75 TUE and the corresponding 75 VUE
images). Figure 14 presents a comparison of the mean scores between TUE and VUE images for
all radiologists and patient exams for each question. Recall that questions 1-5 were based on a 5
point scale, and question 6 was based on a 3 point scale.

TUE vs. VUE
5.0
TUE

4.5

4.26

Average Score

4.0
3.5
3.0
2.5

3.61

4.02

3.42

VUE

3.78 3.76

3.32

3.16
2.38
2.15

1.98

2.0
1.5

1.00

1.0
0.5
0.0

Q1

Q2

Q3

Q4

Q5

Q6

Figure 14. Comparison of mean TUE and VUE scores
The results were fitted with a Bayesian Hierarchical model to determine if VUE images
were non-inferior to TUE images. This model was used for analysis to quantify and account for
uncertainties, such as inter- and intra-observer variability. The results from this analysis are given
in Table 10.
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Mean

Standard

95% Credible

Difference (β)

Deviation

Interval

Q1 [Visualization of Vessels]

-0.514

0.055

(-0.624, -0.408)

Q2 [Pancreatic Contour]

-0.092

0.051

(-0.195, 0.004)

Q3 [Visualization of Calcifications]

-0.127

0.047

(0.216, 0.029)

Q4 [Depiction of Liver Parenchyma]

-0.682

0.052

(-0.786, -0.582)

Q5 [Visualization of Adrenal Glands]

-0.013

0.048

(-0.104, 0.084)

Q6 [Corticomedullary Differentiation]

1.379

0.039

(1.304, 1.455)

Question

Table 10. Qualitative study results from the Mixed Effects Model Analysis
Intra-observer variability was calculated for each radiologist individually. This parameter was
evaluated based on the random subset of 15 patient exams that were repeated during the study.
The associated variability is included in the mixed effects model analysis, as described above.
The results for each radiologist are shown in the figures in Appendix 6.5.
In addition to the mixed effects model analysis, the Kappa statistics for intra-observer
variability were calculated for each radiologist and the results are shown in Tables 11-12.
Radiologist 1
.

Kappa
Coefficient

Radiologist 2

Strength of
Kappa
Agreement
Coefficient
[42]

Radiologist 3

Strength of
Agreement
[42]

Kappa
Coefficient

Strength of
Agreement
[42]

Q1 TUE

0.386

Fair

0.079

Slight

0.566

Moderate

Q2 TUE

0.327

Fair

0.355

Fair

0.634

Substantial

Q3 TUE

0.339

Fair

0.259

Fair

-0.059

Less than
chance

Q4 TUE

0.502

Moderate

0.336

Fair

0.639

Substantial

Q5 TUE

0.472

Moderate

0.101

Slight

0.348

Fair

Q6 TUE

1.00

Perfect

1.00

Perfect

1.00

Perfect

Table 11. Kappa Statistics for Intra-observer Variability (TUE images)
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Q1 VUE

0.828

Almost
Perfect

0.242

Fair

0.234

Fair

Q2 VUE

0.712

Substantial

0.571

Moderate

0.526

Moderate

Q3 VUE

0.298

Fair

0.013

Slight

1.00

Perfect

Q4 VUE

0.336

Fair

0.828

Almost Perfect

0.4

Fair

Q5 VUE

0.439

Moderate

0.268

Fair

0.231

Fair

Q6 VUE

0.545

Moderate

0.268

Fair

-0.119

Less than
chance

Table 12. (Continued) Kappa Statistics for Intra-observer variability (VUE images)

Inter-observer variability was characterized between the three radiologists that participated in the
experiment. This variation between radiologists is also accounted for in the Bayesian Hierarchical
model, and is shown visually Figure 15.

Inter-observer Variability
Radiologist 1 (TUE)
Radiologist 2 (TUE)
Radiologist 3 (TUE)
Radiologist 1 (VUE)
Radiologist 2 (VUE)
Radiologist 3 (VUE)

Average Score

5
4
3
2
1
0

Q1

Q2

Q3

Q4

Q5

Figure 15. Inter-observer variability between Radiologists
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Q6

4.1.2 Discussion: Sub Aim 1.1
The Likert scale for each question presented to each radiologist was discrete in
increments of 1 point. As a result of the discrete nature of the scale, the VUE images were
considered to be non-inferior to TUE images if the difference in answers for each question was
within -0.5 points or greater. This accounted for circumstances in which a radiologist may have
felt the appropriate response to a given question was, for example 3.5, yet had to choose either 3
or 4 as the answer, which is a departure of 0.5 from the true perceived difference. The ability to
recognize an image as TUE or VUE may have influenced the decision, in this example, to choose
3 or 4. Therefore, the -0.5 threshold was used to control for any potential bias.
The results of this study are summarized in Table 13, where β represents the mean
difference between VUE and TUE images calculated using the Bayesian Hierarchical model.
Recall that this model took into account several factors of variability associated with the study,
and is therefore not a raw mean difference.
Question

Results

1. Visualization of major vessels

Uncertain (β = -0.514)

2. Visually sharp reproduction of pancreatic contour

Non-inferior (β = -0.092)

3. Visualization of calcifications

Non-inferior (β = -0.127)

4. Depiction of liver parenchyma

Inferior (β = -0.682)

5. Visualization of adrenal glands

Non-inferior (β = -0.013)

6. Corticomedullary Differentiation

Non-inferior (β = 1.379)

Table 13. Qualitative Study Results Summary
In the Bayesian Hierarchical model the variation was calculated to be σ = 0.563 for interobserver variability and σ = 0.370 for intra-observer variability. Given that the threshold was
chosen to be -0.5, it can be seen that these resulting variations are substantial, indicating the
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necessity for a Bayesian Hierarchical model as opposed to simply using a paired t-test. Notice
that if the conventional t-test had been used to evaluate these data, these variations would not be
accounted for and the associated uncertainty with each result would be substantially greater. A
detailed discussion for the results from each question is given below.
Question 1, evaluating the visualization of major vessels, resulted in statistical
uncertainty regarding the difference between VUE and TUE image scores (β = -0.514). This is
because the 95% credible interval (-0.624, -0.408) contained the -0.5 threshold for differentiation;
therefore, the difference could be attributed to the limited data set acquired as reflected by the
standard deviation. The acquired data set could be increased, which would result in a decrease of
the standard deviation, until the 95% CI no longer contained the -0.5 threshold. In this case, a
definitive statistical result could be obtained. However, statistical uncertainty implies clinical
inferiority. An example comparison of the appearance of the hepatic vein in TUE and VUE
images is provided in Figure 16. The algorithm used to reconstruct VUE images functions by
estimating the volume of iodine in each voxel and replacing it with an equivalent volume of blood
[27]; therefore, the visualization of vessels should theoretically be identical for TUE and VUE
images. As can be seen in Figure 16, this is not the case and the hepatic veins are more clearly
visible in the TUE image. This is possibly due to inaccurate removal of iodine signal from the
image or perhaps differences in the levels of iterative reconstruction applied to TUE and VUE
images. It was noted by each radiologist that visualization of arteries was good, but visualization
of veins was poor in VUE images.

Figure 16. Appearance of hepatic veins in TUE (left) and VUE (right) images
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The greatest (negative) difference between scores for VUE and TUE images was for the
depiction of liver parenchyma (β = -0.682). This is potentially a result of the variation in
reconstruction techniques used for the TUE and VUE images, as described previously. A
common complaint among radiologists when answering this question was that the VUE images
were “grainy” and “noisy”. Iterative reconstruction applied to TUE images but not VUE images
likely reduced noise and the visual appearance of “graininess”, which was more appealing to the
radiologists. This motivated the addition of the third specific aim of the project, which
quantitatively assesses the impact of varying levels of ASIR on enhancement accuracy in VUE
images.
Question 6, concerning corticomedullary differentiation yielded the greatest absolute
difference between VUE and TUE images (β = 1.379), but in for this question VUE images were
scored greater than or equal to TUE images in all cases. All TUE images were given a score of 1,
indicating no corticomedullary differentiation, and scores for VUE images ranged from 2-3,
indicating that there were either slight (2) or extreme (3) differentiation. Corticomedullary
differentiation typically occurs during the corticomedullary phase of renal enhancement, and is a
physiologic process that is observed when there is contrast within the cortex that has not yet
reached the medulla. The corticomedullary differentiation observed in VUE images was a result
of the MSI algorithm inaccurately removing the substantial amounts of iodine signal present in
the post-contrast DECT images, which were acquired during the corticomedullary phase of
enhancement. This differentiation in VUE images is visible even to the untrained eye (Figure 17),
and is an artifact of the MSI algorithm. Although VUE images were scored higher than TUE
images, it should be noted that this result implies that VUE images differ from reality (i.e. TUE
images) where this differentiation is not observed because there is not yet any iodine contrast in
the cortex. Corticomedullary differentiation could potentially be minimized or eliminated by
changing the phase in which the DECT data are acquired [43], e.g. by further delaying the post-
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contrast injection scan time and acquiring the DECT data in the nephrographic phase when renal
enhancement is relatively uniform.

Figure 17. Corticomedullary differentiation in TUE (left) and VUE (right) images
The differences between scores for VUE and TUE images for the reproduction of the
pancreatic contour (β = -0.092) and the visualization of adrenal glands (β = -0.013) were not
statistically significant. The mean difference in scores, represented by β, between TUE and VUE
images was minimal. It was expected that the pancreas and adrenal glands would not be affected
by the MSI algorithm because each does not uptake a significant amount of iodine contrast. Given
the physiological nature of the pancreas and adrenal glands and considering the vascularity of
each, it was expected that the scores would not significantly differ between TUE and VUE
images, and this was experimentally proven to be true.
Although the results for the visualization of calcifications (β = -0.127) indicated that
VUE images were non-inferior to TUE images, this result is misleading. It was noted that each
radiologist at least once during the study suggested that the scoring for calcifications was in
essence binary, i.e. it is seen or not seen. There were cases in which calcifications were seen in
TUE images and not VUE images, and some cases for which the opposite was true (Table 14).
The few cases where calcifications were seen in VUE but not TUE images is likely attributable to
the variability of the observer between scoring the TUE and corresponding VUE image
independently. However, there are more instances where calcifications were seen in TUE images
and not TUE images. This result is consistent with other studies, and has been referred to in the
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literature as the “subtraction artifact” [9]. The subtraction artifact is a result of the inability of the
algorithm to accurately distinguish iodine from other materials with high atomic numbers, such as
calcium. The multi-material decomposition method presumably decomposes a voxel into only
two materials [7], such as water and iodine, which results in all materials contained in a given
voxel being represented as some weighted combination of water and iodine. Since calcium has a
large photoelectric cross-section, a voxel with calcium will be assigned by the algorithm as
containing some percentage of iodine, which is subtracted when the VUE image is reconstructed.
This is apparent is a case where calcifications are not as bright in the VUE as in the TUE, or
when they are not seen at all, as well as when visually comparing the appearance of the spine
between VUE and TUE images.

Radiologist 1

7

1

Radiologist 2

12

2

Radiologist 3

11

4

Subtraction Artifact
Number of Calcifications seen

Number of
Number of
instances
instances
calcifications
calcifications
were seen in TUE were seen in VUE
but not VUE
but not TUE

14

in TUE only

12

in VUE only

10
8
6
4
2
0

Rad. 1

Rad. 2

Rad. 3

Table 14. Comparison of instances in which calcifications were not seen in one of the images
Although there were cases where calcifications were seen in VUE but not TUE, this
occurred much less often than visualization in TUE but not VUE. When considering these cases
of visualization in VUE but not TUE one should consider the large variations calculated in the
mixed effects analysis for inter- and intra-observer variability (σ = 0.563 and 0.370, respectively).
However, the number of instances where calcifications were seen in TUE but not VUE is
substantial, even considering these sources of variation, and is likely not attributable to these
sources of variability. This result instead likely reflects an artifact of the algorithm, which
subtracts calcium signal due to the representation of calcium as a weighted combination of water
and iodine.
44

4.1.3 Results: Sub Aim 1.2
The quantitative study was based on CT number measurements in the patient exams used
in the qualitative study. A plot of the average CT number measured in each region of interest can
be found in Figure 18, and the corresponding quantitative comparison can be found in Table 15.

Comparison of TUE to VUE

250

Mean CT Number (HU)

200
TUE
150

VUE

100
50
0
-50
-100
-150

Figure 18. Comparison of average HU measured in TUE vs. VUE
TUE Mean CT
number (HU)

VUE Mean CT
number (HU)

Spleen

41.4

47.6

Liver

51.2

52.3

Spine

155.3

82.2

Aorta

35.9

44.8

Cortex

27.5

40.4

Medulla

29.1

28.1

Subcutaneous Fat

-99.2

-95.6

IVC

29.4

39.2

Cystic Lesion

16.0

15.1

Table 15. Quantitative results: Average CT numbers
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The fraction of cases where the absolute difference between TUE and VUE
measurements was greater than 10 HU was plotted to visualize where the greatest differences

Difference (% of total)

occurred, as shown in Figure 19.

100
90
80
70
60
50
40
30
20
10
0

Absolute difference above 10 HU

Figure 19. Absolute difference in CT number between TUE and VUE images

The data collected from this study were analyzed using a student’s paired t-test. The ± 6
HU tolerance at 120 kVp for water required by the manufacture for the 750HD DECT scanner
was used as the basis for the determination of a relative threshold. The ± 6 HU tolerance was
converted into an uncertainty about the linear attenuation coefficient of water at 70 keV:
𝟐
𝝁 = 𝟎. 𝟏𝟗𝟒𝟖 ± 𝟎. 𝟎𝟎𝟏𝟐 𝒄𝒎 ⁄𝒈

Equation 4.1.3-1

This equates to a tolerance of ± 0.6% about water. The average CT number measured on the TUE
images for each area of interest was converted to a linear attenuation coefficient, and a ± 0.6%
threshold was calculated about each. The average of the upper and lower tolerances (i.e. -0.6%
and +0.6%) was calculated, converted back to CT number (HU) and used as the threshold for
each organ. The thresholds used for the t-test are given in Table 16.
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Mean CT
number (HU)

µ (cm-1)

0.6% tolerance
in µ (cm-1)

± HU

Spleen

41.4

0.203

0.0012

6.25

Liver

51.2

0.205

0.0012

6.31

Spine

155.3

0.225

0.0014

6.93

Aorta

35.9

0.202

0.0012

6.22

Cortex

27.5

0.200

0.0012

6.16

Medulla

29.1

0.201

0.0012

6.17

Fat

-99.2

0.176

0.0011

5.41

IVC

29.4

0.201

0.0012

6.18

Table 16. Determination of Threshold of differentiation
The results of this study are summarized in Table 17 below. A p-value of < 0.05 indicated
that VUE images were non-inferior to TUE images, and was calculated based on the threshold
determined for each area of interest. A p-value of ≥ 0.05 indicated that VUE images were inferior
to TUE images.
95% CI for the

Organ

P-value

Spleen

0.815

(-7.53, -5.01)

Inferior

Liver

< 0.001

(-0.85, 3.05)

Non-inferior

Spine

1.000

(64.12, 82.23)

Inferior

Aorta

0.999

(6.57, 11.13)

Inferior

Cortex

1.000

(10.69, 15.25)

Inferior

Medulla

< 0.001

(-0.82, 2.86)

Non-inferior

Subcutaneous Fat

0.676

(1.71, 5.11)

Inferior

Inferior Vena Cava

0.999

(-7.42, 12.24)

Inferior

difference

Table 17. Quantitative results summary
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Results

4.1.4 Discussion: Sub Aim 1.2
The thresholds used for statistical analysis were based on physics principals, and
therefore leave open the question of the clinical relevance of the results. Consider, for example,
the results for the spleen (based on a ± 6.25 HU threshold). The t-test indicated that VUE images
are inferior to TUE images, but the 95% confidence interval (CI) indicates that VUE images will
measure within -7.53 HU of TUE images. To assess the clinical relevance of these results, an
evaluation of the implications of the variation in CT number on a grayscale image was conducted.
The purpose of this assessment was to determine if the variation in CT number between TUE and
VUE images, based on the calculated 95% CI, would even be perceivable to a radiologist.
The evaluation was done for a window width/ window level (WW/WL) of 500/50, which
is a common default setting for abdominal image viewing. For an image displayed on a 10 bit
monitor 1,024 grayscales are available which equates to approximately 2 gray levels per HU. If it
is assumed that the human eye can perceive between 64-128 shades of gray, then a change in
every 4-8 HU would be perceived by the human observer. Referring to Table 17, the 95% CI for
the spleen and subcutaneous fat indicate that there is likely no clinical significance to these results
and that from a clinical perspective measurements for the spleen and fat for VUE images are not
inferior to TUE images.
Figure 20 demonstrates differences in the appearance of bone between TUE and VUE
images. Notice that the spine appears much brighter in the TUE image, which could be a
consequence of the inability of the material suppression algorithm to accurately distinguish bone
from an iodine-blood mixture. This has been referred to in the literature as a “subtraction artifact”
[9]. For this feasibility study, the subtraction of calcium signal in the spine is likely irrelevant for
assessment of renal masses.
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Figure 20. Comparison of spine appearance in TUE (left) to VUE (right)

4.1.5 Dose Considerations
The volume computed tomography dose index (CTDIvol) was recorded from the dose
report for each patient exam. The average CTDIvol for the pre-contrast phase (TUE) well as for
the total CT exam are given in Table 18. Note that the reduction (%) is representative of the
particular exam protocol used for patients in the retrospective study, which involves acquisition
of multiple post contrast images. For renal protocols, which typically involve the acquisition of
fewer post-contrast images, the reduction in CTDIvol (%) resulting from elimination of the precontrast phase would be a larger fraction of the total.
Mean
Values

Total
Age
Number (N) (years)

Weight
(kg)

BSA
(m2)

CTDIvol for Total CTDIvol
TUE (mGy)
(mGy)

Reduction
(%)

Women

27

62.3

70.8

1.96

11.0

113.8

9.7

Men

33

62.0

67.9

1.94

10.8

127.7

8.5

Overall

60

62.1

74.6

1.90

10.5

121.5

8.7

Table 18. Estimated doses from the pre-contrast images for patient exams
4.1.6 Limitations of the retrospective study
The raw CT data for the patient exams used in this study were no longer available;
therefore the TUE and VUE images could not be reconstructed using identical techniques. The
TUE images were reconstructed with 60% ASIR and the SOFT reconstruction filter, whereas the
DECT data used to reconstruct VUE images were reconstructed with 0% ASIR and the
STANDARD reconstruction filter.
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4.2 Specific Aim 2
4.2.1 Technical Notes
4.2.1.1 Results and discussion: Iodine concentration determination
CT numbers were measured for each Optiray-water mixture and plotted to determine a
relationship between CT number and iodine concentration. The results were plotted and linear
regression was used to estimate a relationship between CT number and iodine concentration, as
shown in Figure 21. The CT numbers predicted from previous experiments [38] are plotted
alongside the CT numbers measured in this experiment. The relationship between CT number and
iodine concentration was determined to be:

Iodine Concentraetion
(mg/mL)

𝑚𝑔
𝐼𝑜𝑑𝑖𝑛𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 ( ⁄𝑚𝐿) = 0.0501 ∗ (𝐶𝑇 𝑛𝑢𝑚𝑏𝑒𝑟) − 1.08

𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 4.2.1.1 − 1

Correlation between Iodine concentration and CT number

22
20
18
16
14
12
10
8
6
4
2

Measured HU
Predicted HU

y = 0.0501x - 1.08
R² = 0.9974

50

150

250
350
CT number (HU)

450

Figure 21. Correlation between iodine concentration (mg/mL) and CT number (HU)
The variation between predicted CT number from previous experimentation and the
measured data is likely reflective of the variation between energy spectra from CT scanner to CT
scanner.
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4.2.1.2 Results and discussion: Phantom set-up verification
VUE images were reconstructed from DECT imaging of the Jaszczak phantom. The
results of the experiment for the 31.8 mm diameter sphere (sphere 1) are plotted in Figure 22, and
Figure 23 for the 25.4 mm sphere (sphere 2). The results of the Jaszczak phantom study indicate
that the output of the MSI algorithm for VUE image reconstruction is substantially the same in
both in positive and negative contrast backgrounds. Encouraged by these results, we proceeded
with Sub Aim 2.2 of the phantom study.
CT number measuremed in VUE images (Sphere 1)

CT Number (HU)

30
25
20
15
10

VUE - Phantom

5

VUE - Patient

0
0

1

2
3
4
Measurement (slice number)

5

6

Figure 22. Positive versus negative contrast comparison for Sphere 1
CT number measured in VUE images (Sphere 2)

30

CT Number (HU)

25
20
15
10
VUE - Phantom

5

VUE - Patient

0
0

1

2
3
Measurement

4

5

6

Figure 23. Positive versus negative contrast comparison for Sphere 2
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4.2.2 Results: Sub Aim 2.2
The measured CT number and noise for each preset imaged with the medium phantom
can be seen in Figures 24 and 25, respectively. Four GSI protocols were selected for imaging the
small and medium phantom sizes, and four protocols were selected for imaging the large

CT Number (HU)

phantom.
VUE CT number measurements for 3 cm sphere

20
18
16
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8
6
4
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GSI Preset

Standard Deviation (HU)

Figure 24. VUE CT number measurements for each GSI protocol
Noise Comparison for 3 cm sphere

14
12
10
8
6
4
2
0
0

5

10

15

20

25

30

35

40

45

50

55

60

GSI Preset

Figure 25. VUE image noise measurements for each GSI protocol
The protocols selected for use in Sub Aim 2.2 are listed in Table 19. GSI preset 10 was
selected for imaging all three phantoms to bridge the gap between clinical practices and the
retrospective study for further investigation of other presets in the phantom study. Preset 10 was
used in image acquisition of almost all patient cases in the retrospective study independent of
patient size.
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Used for
small and
medium
phantoms

Used for
large
phantom

Bowtie

Beam
Width
(mm)

Rotation
Time (s)

mA

CTDIvol
(pitch
0.969)

10

Large

40

0.8

600

25.5

11

Medium

40

0.8

600

26.7

16

Medium

40

0.6

640

22.9

29

Medium

20

0.8

550

27.6

36

Large

40

0.8

360

10.3

10

Large

40

0.8

600

25.5

12

Large

20

0.8

600

28.2

22

Large

40

0.7

375

10.8

GSI
Preset

Table 19. Selected GSI presets

4.2.3 Discussion: Sub Aim 2.2
It was difficult to assess the accuracy of VUE image CT numbers compared to the TUE
image baseline, which was acquired with water in the phantom inserts. Recall that the MSI
algorithm used to reconstruct VUE images subtracts the iodine concentration contained within
each voxel and replaces it with an equivalent volume of blood [27]. As a result, the TUE images
acquired with water in the spheres will not be representative of what is expected from the VUE
images, which would in theory be a blood-water mixture after the iodine replacement. The TUE
images used in the experiment with water filled spheres provided a baseline measurement of
approximately 0 HU, whereas the VUE images resulted in an average measurement of 13 HU for
the 3 cm sphere.
An experiment was conducted in an attempt to estimate the expected baseline VUE
measurement that could be used for comparison of GSI protocols. Mixtures of water and iodine
were prepared with increasing iodine concentrations, and CT numbers were measured in the
resulting VUE images. CT number (HU) was plotted against iodine concentration (mg/mL) and
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the relationship was extrapolated to zero to estimate what the expected CT number would be for 0
mg/mL iodine concentration, which resulted in an expected baseline VUE measurement of 14.7
HU. The prominent issue with this method was that a GSI protocol had to be selected in order to
acquire DECT datasets for VUE image reconstruction; therefore, the results are inherently biased
toward that protocol. Since the goal of this Sub Aim is to select the top candidate protocols, this is
problematic. As a result, four GSI candidate protocols were selected by careful evaluation of the
full protocols list, taking into consideration measured image noise and the specific technique
parameters.
The GSI protocols were selected to allow for variation in CT acquisition parameters
between protocols, as well as with consideration to the amount of noise measured from each.
For the medium and small phantoms (refer to Table 19):
•

GSI 10 selected because of common clinical use

•

GSI 10 → GSI 11 variation in bowtie filter

•

GSI 11 → GSI 16 variation in rotation time and mA

•

GSI 16 → GSI 29 variation in beam width

For the large phantom (refer to Table 19):
•

GSI 10 selected because of common clinical use

•

GSI 36 → GSI 10 variation in mA, mAs, and CTDIvol

•

GSI 10 → GSI 12 variation in beam width

•

GSI 12 → GSI 22 variation in rotation time and mA

Example images acquired using each selected preset at the same location in the small phantom
with 5.00 mm thickness are shown in Figure 26, and example images of each preset selected for
the large phantom are shown in Figure 27.
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Figure 26. Example images of the medium phantom for the selected GSI presets (from left
to right) GSI 10, 11, 16, and 29

Figure 27. Example images of the large phantom for the selected GSI presets (from left to
right) GSI 10, 12, 22, and 36

Limitations of Sub Aim 2.2
In order to make a more accurate comparison of the performance of each GSI protocol in
relation to the expected TUE measurement, the experiment would need to be conducted with
blood only for TUE image acquisition, and a blood-iodine mixture for DECT image acquisition.
This would allow for reconstruction of VUE images expected to have CT number similar to the
TUE images, considering the nature of the MSI algorithm. Using blood would allow for an
assessment of the variation of CT numbers for all GSI protocols to TUE image CT numbers.
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4.2.4 Results: Sub Aim 2.3
A Bayesian Hierarchical model was used to analyze all phantom data. This method was
chosen because. This model was chosen to allow for direct quantification of uncertainty resulting
from many parameters in the study, including variation in lesion size, patient size, enhancement,
etc. Note that the error bars for each graph in the subsequent sections represent ± σtotal (equation
3.2.4-2). Additional graphs for each section can be found in Appendix 6.6.
Scenario 1
Each phantom was imaged in varying configurations for a baseline CT number of
-100 HU, simulated with vegetable oil in the inserts. Because there was no enhancement for this
scenario, a direct comparison was made for VUE vs. TUE CT number measurements. Graphs of
varying parameters can be seen in Figures 28 and in Appendix 6.6. The results of the Bayesian
Hierarchical model for comparison of VUE techniques to TUE images are quantitatively
summarized in Table 20 in the following section.

Small

Medium

VUE-36

VUE-22

VUE-12

VUE-10

TUE

VUE-29

VUE-16

VUE-11

VUE-10

TUE

VUE-29

VUE-16

VUE-11

VUE-10

0
-20
-40
-60
-80
-100
-120

TUE

CT Number (HU)

Variation in GSI protocol

Large

Figure 28. Evaluation of the impact of GSI protocol on CT number in VUE vs. TUE images.
Plotted data represent the 1 cm sphere in the center of the FOV.
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Scenario 2
Each phantom was imaged in varying configurations for a baseline CT number of
0 HU, simulated with distilled water in the inserts. Because there was no enhancement for this
scenario, a direct comparison was made for VUE vs. TUE CT number measurements.

Comparison of GSI presets for all phantoms
10
0
-10

Small

Medium

VUE-36

VUE-22

VUE-12

VUE-10

TUE

VUE-29

VUE-16

VUE-11

VUE-10

TUE

VUE-29

VUE-16

VUE-11

-30

VUE-10

-20
TUE

CT Number (HU)

20

Large

Figure 29. Comparison of each GSI preset to TUE CT number measurements for the 1 cm
lesion size located in the center of the SFOV.
For scenarios 1 and 2, the TUE and VUE CT number measurements were directly
compared, because there was no enhancement in post-contrast images. As a result, a single model
was used for statistical analysis of these scenarios. Table 20 quantitatively represents the results
of each GSI protocol as compared to the TUE image measurements. Note that the results are
given as the difference between each VUE protocol as compared to the TUE measurements,
taking into account uncertainties from each variable. The posterior probability can be interpreted
as:


Posterior probability > 0.95 implies significant positive variation of VUE images



Posterior probability < 0.05 implies significant negative variation of VUE images



Posterior probability = 0.5 implies no significant difference between VUE and TUE
images
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The results from the Bayesian Hierarchical model, shown in Table 20, indicate that there
is no statistically significant variation between each VUE protocol and the TUE images across a
wide range of varying parameters (including lesion size and position of the lesion within the field
of view) for simulated angiomyolipoma and benign cystic lesions. The parameter σProtocol given in
Table 20 represents the standard deviation in CT number measurements resulting from
differences in GSI protocol, as computed by the Bayesian Hierarchical model.

Small Phantom

Medium Phantom

Large Phantom

95% CI for
difference

Posterior
Probability

95% CI for
difference

Posterior
Probability

95% CI for
difference

Posterior
Probability

VUE-10 [10]

(-1.437, 2.380)

0.564

(-2.111, 1.838)

0.502

(-10.246, 1.006)

0.238

VUE-11 [12]

(-1.297, 2.434)

0.555

(-1.786, 2.239)

0.515

(-9.990, 1.026)

0.25

VUE-16 [22]

(-1.441, 2.704)

0.56

(-1.252, 2.973)

0.56

(-11.138, 0.916)

0.226

VUE-29 [36]

(-1.595, 2.148)

0.524

(-1.584, 2.360)

0.531

(-8.871, 1.353)

0.273

σProtocol

(0.029, 2.388)

--

(0.029, 2.582)

--

(0.037, 7.302)

--

Table 20. Bayesian Hierarchical Model results for scenarios 1 and 2. The presets in brackets
are those used for the large phantom.
Scenario 3
For Scenarios 3-5, the enhancement values of interest will be labeled as follows in each
of the graphs:
𝑽𝑼𝑬 𝒊𝒎𝒂𝒈𝒆 𝒃𝒂𝒔𝒆𝒅 𝒆𝒏𝒉𝒂𝒏𝒄𝒆𝒎𝒆𝒏𝒕: ∆𝑉𝑈𝐸 = 𝐷𝐸𝐶𝑇𝑝𝑜𝑠𝑡−𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 − 𝑉𝑈𝐸
𝑻𝑼𝑬 𝒊𝒎𝒂𝒈𝒆 𝒃𝒂𝒔𝒆𝒅 𝒆𝒏𝒉𝒂𝒏𝒄𝒆𝒎𝒆𝒏𝒕: ∆𝑇𝑈𝐸 = 𝑆𝐸𝐶𝑇𝑝𝑜𝑠𝑡−𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 − 𝑇𝑈𝐸
The error bars in graphs shown in Scenarios 3-5 represent ± σtotal (as described in section 3.2.4),
where the term for standard deviation within each ROI measurement (σN) was added in
quadrature for pre- and post-contrast measurements to estimate the error for enhancement.
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Each phantom was imaged in varying configurations for a baseline CT number of
20 HU, simulated with an apple juice and distilled water mixture in the inserts. For this scenario
two cases were simulated to mimic low and intermediate enhancement. Recall that one solution
was made and used for all variation in phantom configuration, including phantom size. As can be
seen in Figure 30, the same solution measured different CT numbers across patient size. This
variation in measured enhancement across patient size is not problematic because the same
solution was used to acquire SECT and DECT post-contrast images for each phantom, which is
the comparison of interest for this study.

Variation in GSI protocol and enhancement

Enhancement (HU)
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∆VUE(16)
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∆TUE

∆VUE(29)

∆VUE(16)

∆VUE(11)

∆VUE(10)
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Figure 30. Scenario 3: Comparison of enhancement with TUE vs. VUE as the baseline
image for varying patient size, enhancement, and GSI presets for the 3 cm sphere located in
the periphery of the SFOV
Scenario 3 was unique from all other scenarios because a baseline value of 20 HU was simulated.
As a result, an individual Bayesian Hierarchical model was used to fit the data for this scenario to
most effectively quantify the uncertainties and determine the posterior probability. The results are
given as the difference between enhancement values for each GSI protocol as the baseline image
compared to measurements with TUE images as the baseline, taking into account uncertainty
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resulting from each parameter. As previously stated the posterior probability can be interpreted
as:


Posterior probability > 0.95 implies significant positive variation of VUE images



Posterior probability < 0.05 implies significant negative variation of VUE images



Posterior probability = 0.5 implies no significant difference between VUE and TUE
images

The results from the Bayesian Hierarchical model, shown in Table 21, indicate that there are
significant differences between each enhancement from each VUE protocol and the TUE images
across a wide range of varying parameters (including lesion size and position of the lesion within
the field of view) for simulation of Bosniak category II-IIF lesions. The 95% credible interval is
representative of the difference in enhancement values from each GSI protocol to the TUE
images, which is significant. This is also demonstrated visually in Figure 30.

Small Phantom

Medium Phantom

Large Phantom

95% CI for
difference

Posterior
probability

95% CI for
difference

Posterior
probability

95% CI for
difference

Posterior
probability

VUE-10 [10]

(-18.312, -14.531)

0

(-15.565, -12.176)

0

(-10.263, -4.618)

0

VUE-11 [12]

(-18.339, -14.574)

0

(-15.948, -12.570)

0

(-9.650, -3.942)

0

VUE-16 [22]

(-18.458, -14.613)

0

(-15.783, -12.370)

0

(-11.324, -5.851)

0

VUE-29 [36]

(-18.106, -14.423)

0

(-16.008, -12.634)

0

(-10.238, -4.622)

0

σProtocol

(4.359, 21.15)

--

(3.759, 18.258)

--

(1.954, 10.482)

--

Table 21. Bayesian Hierarchical Model results for scenario 3. The presets in brackets are
those used for the large phantom.
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Simulation 4
Each phantom was imaged under varying configurations for a baseline CT number of
40 HU simulated with an apple juice and distilled water mixture in the inserts. For this scenario
low enhancement (5-10 HU) and intermediate (15- 20 HU) enhancement cases were simulated.

Variation in GSI protocol and enhancement
Low enhancement
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8
6
4
2
0
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-4

∆TUE

Enhancement (HU)

Graphs of different parameters can be seen in Figure 31 and in Appendix 6.6.

Large

Figure 31. Scenario 4: Comparison of enhancement with TUE vs. VUE as the baseline
image for varying patient size, iodine concentrations, and GSI presets for the 3 cm sphere
located in the periphery of the SFOV
Scenarios 4 and 5 simulated as baseline lesion measuring 40 HU, and then varying
enhancement situations were simulated. Consequently, a separate Bayesian Hierarchical model
was used to fit this data, and is shown in Table 22.
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Scenario 5
Each phantom was imaged under varying configurations for a baseline CT number of 40
HU simulated with an apple juice and distilled water mixture in the inserts. For this scenario only
high enhancement (40 HU) was simulated to mimic a Bosniak category IV lesion that is clearly
malignant. Figure 32 shows a comparison of enhancement measurements with each GSI protocol
used as the baseline for calculation compared to TUE baseline measurements.

Variation in GSI protocol
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Figure 32. Scenario 5: Comparison of enhancement with TUE vs. VUE as the baseline
image for varying patient size and GSI presets for the 3 cm sphere located in the periphery
of the SFOV
The results from the Bayesian Hierarchical model, shown in Table 22, indicate that there are
significant differences between enhancement measurements for each baseline VUE image and the
TUE images across a wide range of varying parameters (including lesion size and position of the
lesion within the field of view). The 95% credible interval is representative of the difference in
enhancement values from each GSI protocol to the TUE images, for which significance is
demonstrated by a posterior probability of 0 for all protocols across all phantom sizes. This is also
demonstrated visually in Figure 31. The parameter σProtocol is the variation between enhancement
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for all VUE and TUE image based measurements, as calculated from the Bayesian Hierarchical
model.
Small Phantom

Medium Phantom

Large Phantom

95% CI for
difference

Posterior
probability

95% CI for
difference

Posterior
probability

95% CI for
difference

Posterior
probability

VUE-10 [10]

(-10.469, -5.940)

0

(-12.028, -5.740)

0

(-13.234, -6.247)

0

VUE-11 [12]

(-12.113, -7.324)

0

(-13.123, -6.705)

0

(-11.166, -4.593)

0

VUE-16 [22]

(-11.791, -7.013)

0

(-12.918, -6.201)

0

(-14.340, -7.332)

0

VUE-29 [36]

(-11.417, -6.491)

0

(-12.168, -5.508)

0

(-11.608, -5.021)

0

σProtocol

(2.386, 12.267)

--

(2.402, 12.672)

--

(2.384, 12.862)

--

Table 22. Bayesian Hierarchical Model results for scenario 3. The presets in brackets are
those used for the large phantom.
Position of the simulated lesion within the field of view was varied between the center
and periphery locations of the phantom, as shown in Figure 7. The standard deviation resulting
from position of the lesion within the FOV was estimated using probabilities from the Bayesian
Hierarchical model. The deviation, σFOV, is shown in Table 23. The posterior probabilities
calculated from the Bayesian Hierarchical model indicate significant differences in CT number
(scenarios I and II) and enhancement (scenarios III-V) measurements resulting from different
locations within the FOV in VUE enhancement measurements for all scenarios. Previous studies
have also found that the material decomposition function of GSI using a GE CT750 HD scanner
is dependent on position within the FOV for varying iodine concentrations, and may be
attributable to beam hardening in FOV locations where CT number uncertainty was high [44].
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Scenario

I - II
III
IV - V

Small Phantom

Medium Phantom

Large Phantom

95% CI for
variation (σFOV)

Ext Val

95% CI for
variation

Ext Val

95% CI for
variation (σFOV)

Ext Val

(0.055, 8.099)

1

(0.031, 2.587)

1

(0.063, 8.139)

1

(0.074, 1.994)

1

(0.061, 1.793)

1

(0.033, 2.437)

1

(0.031, 2.170)
1
(0.033, 3.343)
1
(0.070, 3.928)
Table 23. Variation in FOV for each Scenario (σFOV)

1

Change in lesion size was considered as a variable by imaging lesions 1 cm, 2 cm, and 3
cm in diameter for each patient size, as shown in Figure 6. The standard deviation resulting from
lesion size for each scenario, σLESION, was calculated in the Bayesian Hierarchical model and is
shown in Table 24.
Small Phantom
Lesion
Scenario
size

III

Large Phantom

95% CI for
95% CI for
95% CI for
Posterior
Posterior
Posterior
variation (σLESION) probability variation (σLESION) probability variation (σLESION) probability

1 cm

(-2.125, 0.857)

0.197

(-2.301, 0.773)

0.154

(-5.191, 0.824)

0.074

2 cm

--

--

--

--

--

--

3 cm

(-0.391, 2.477)

0.928

(-0.726, 2.099)

0.849

(-2.489, 3.120)

0.587

0.127

(-6.758, 0.024)

0.026

(-4.903, 1.393)

0.138

1 cm (-4.0766, 1.0409)
IV - V

Medium Phantom

2 cm

--

--

--

--

--

--

3 cm

(-0.667, 4.237)

0.922

(-0.986, 5.909)

0.921

(-1.558, 4.157)

0.828

Table 24. Variation resulting from lesion size for scenarios where enhancement was
simulated (σLESION)
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The standard deviation attributed to changing lesion size, σLESION, was computed for the 1
cm and 3 cm lesions relative to the deviation of each from measurements in the 2 cm sphere.
Significant differences between VUE and TUE enhancement measurements (posterior probability
> 0.95 or posterior probability < 0.05) for the 1 cm sphere could be a result of partial volume
averaging because the image thickness used throughout the study was 5 mm. Notice that the most
change due to lesion size was observed in scenarios I and II, and could be attributable to the large
differences in baselines values (-100 for scenario I and 0 for scenario II) considered in the model.
4.2.5 Discussion: Sub Aim 2.3
For discussion of the results of the phantom study, the enhancement values of interest
will be labeled as follows:
𝑽𝑼𝑬 𝒊𝒎𝒂𝒈𝒆 𝒃𝒂𝒔𝒆𝒅 𝒆𝒏𝒉𝒂𝒏𝒄𝒆𝒎𝒆𝒏𝒕: ∆𝑉𝑈𝐸 = 𝐷𝐸𝐶𝑇𝑝𝑜𝑠𝑡−𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 − 𝑉𝑈𝐸
𝑻𝑼𝑬 𝒊𝒎𝒂𝒈𝒆 𝒃𝒂𝒔𝒆𝒅 𝒆𝒏𝒉𝒂𝒏𝒄𝒆𝒎𝒆𝒏𝒕: ∆𝑇𝑈𝐸 = 𝑆𝐸𝐶𝑇𝑝𝑜𝑠𝑡−𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 − 𝑇𝑈𝐸
It has been stated that the determination of enhancement is the most important criterion
used to distinguish surgical from nonsurgical renal masses [17]. Based on the calculated
difference between pre- and post-contrast images, a lesion is placed into one of the following
categories [17]:
•

Unenhancing: difference is < 10

•

Indeterminate (and needs further evaluation): difference is between 10 -20 HU

•

Enhancing: difference is > 20 HU

In light of this it is clear that accurate quantification of enhancement is crucial for borderline
lesions, in the range of approximately 5-25 HU (when considering systematic and random error),
for appropriate diagnosis of renal lesions. Considering the results of Scenarios 3 and 4 in the
phantom study, it is clear that VUE as the baseline image for enhancement measurement is not a
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suitable replacement for TUE images. As demonstrated in Figures 30-31 there were cases in
which VUE-based enhancement measurements would have led to different categorization of the
simulated lesions than TUE-based enhancement measurements. Because enhancement was
always lower for VUE-based measurements, this led to categorization of “unenhancing” in many
cases where the TUE-based measurements would have led to categorization of an “enhancing” or
“indeterminate” lesion (requiring surgical resection or further evaluation). The clinical
implications of these differences in enhancement values could be severe and lead to false negative
diagnosis of renal lesions. Table 25 quantifies the number of times that VUE-based enhancement
measurements lead to different categorization than TUE-based measurements for Scenarios III-V.
As previously stated, the categories were considered to be unenhancing (HU < 10), intermediate
(10 < HU > 20), or enhancing (HU > 20).
Total

Scenario III

Scenarios IV-V

Number of samples

650

288

362

Number of times
categorization did not match

373

229

144

Number of times
categorization did match

277

59

218

Accuracy (%)

42.6%

20.5%

60.2%

Table 25. Comparison of categorization of TUE and VUE measurements to evaluate clinical
relevance of the results
The percentage of matching categorization is higher for Scenarios IV-V because this
includes data from Scenario V, which simulated a highly enhancing renal lesion (approximately
40 HU enhancement). Although differences between enhancement measurements were significant
in Scenario V, they rarely led to differences in categorization of the lesion as enhancing or nonenhancing. For example, a difference of 10 HU in enhancement between TUE- and VUE-based
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data for a borderline lesion enhancing 20 HU is more clinically meaningful than the same
difference for a lesion that enhances a total of 50 HU. This experiment has demonstrated that for
highly enhancing renal lesions, enhancement calculations for TUE and VUE images would lead
to the same categorization of the lesion, and therefore confirm that VUE images would be a
feasible replacement to TUE images in these cases. However, the results of scenario III-IV
indicate that enhancement differences between VUE-based compared to TUE-based
measurements are too significant; therefore the results of this study indicate that it is not feasible
to replace TUE with VUE images in lesions which contain low concentrations of iodine in postcontrast imaging. Recall that multiphase renal CT exams are performed to characterize and
diagnose renal lesions, the nature of which is not known prior to examination. As a result, VUE
images are not a suitable replacement for TUE images for determination of enhancement because
the feasibility could not be demonstrated in the cases of all lesion types studied in these
experiments.
The presets that returned results that matched most closely to TUE based enhancement
measurements were determined for each scenario by the Bayesian Hierarchical model, which
quantified and accounted for sources in uncertainty resulting from the many parameters in the
experiment. A summary of these results for all scenarios can be found in Table 30 in Appendix
6.6. For the small phantom GSI-29 most closely matched TUE measurements and for the medium
phantom GSI-10 most closely matched. For the large phantom the protocol most closely matching
TUE measurements varied for each scenario.
A note should also be made regarding the subtraction artifact, which was also observed in
the retrospective study and discussed in section 4.1.4. A delrin rod with a CT number of
approximately 300 HU was included in the phantom design to simulate spine. A subset of images
was randomly selected for ROI measurements in the spinal region, the dimensions of which are
given in Table 7. Figure 33 shows a comparison of each GSI preset to the TUE CT number
measurement.
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CT number comparison for simulated spine

330
320
310
300
290

Small

Medium

MSI36

MSI22

MSI12

MSI10

TUE

MSI29

MSI16

MSI11

MSI10

TUE

MSI29

MSI16

MSI11

MSI10

280

TUE

Mean CT Number (HU)

340

Large

Figure 33. Comparison of VUE to TUE CT numbers measured in the delrin rod, which
simulated bone.
For all measurements, the CT number measured in the VUE images was less than that
measured in the TUE image. This further confirms the presence of the subtraction artifact in
images reconstructed using the MSI algorithm. This is explained by the representation of all
materials within each voxel as a weighted combination of water and iodine. As demonstrated in
Figure 1 (section 1.3), the algorithm interprets bone as a weighted combination of water and
iodine, and therefore removes the calculated fraction of iodine present resulting in removal of
calcium signal in the reconstructed VUE image.
Measurements of the phantom background were recorded in a subset of images to
compare the CT number in TUE to VUE images. As shown in Figure 34, the average
measurements made in the phantom background are similar for TUE and VUE images, which is
expected because these high density polyethylene regions did not contain iodine contrast.
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Phantom Background
CT Number (HU)

-5
-15
-25
-35
-45
-55
-65
-75

Figure 34. Comparison of each GSI preset to the average TUE CT number measured in the
background of the phantom
Limitations of this study:
The MSI algorithm has been stated to replace the estimated volume of iodine with an
equivalent volume of blood [27]. In light of this, use of blood for TUE baseline image
acquisition, and then use of blood and Optiray mixtures would have been the most preferable
experimental approach. However, due to limitations regarding the accessibility of blood, a
surrogate material was used in instead of blood. The surrogate material selected was apple juice,
due to the similarities in attenuation measurements and effective atomic numbers. The use of this
surrogate in place of blood could have affected the results, and therefore this limitation should be
considered with the results.
The phantom background is HDPE (approximately -65 HU), which has a spectral curve
which varies from that of soft tissue, which potentially affected DECT measurements. The
Jaszscak phantom study verified that this variation is minimally significant for VUE CT number
measurements (Figures 22-23), but it was signification for DECT measurements. Consequently,
the use of HDPE as the background material could have affected DECT post-contrast
measurements, which would have in turn affected enhancement measurements.
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Previous studies have sought to identify the optimal monochromatic keV to match 120
kVp SECT images [45]. Some preliminary results have indicated that this value may be 68 keV
instead of the commonly used 70 keV. Using 70 keV for comparison to 120 kVp SECT images
therefore may not be the most accurate comparison, which could affect the post-contrast
measurements and consequently overall enhancement. This was assessed by measuring CT
numbers for varying monochromatic energies to estimate the potential difference that could result
if the 70 keV used in these experiments is not the optimal monochromatic energy for postcontrast images. An example of the difference for Scenarios III (intermediate enhancement) and
IV (low enhancement) is shown in Table 26. The difference between the potentially more suitable
68 keV and the currently used 70 keV is approximately 1 HU for each case considered. Referring
to Figures 30-31 (visually) and Tables 21-22 (quantitatively), the difference in enhancement is
larger than 1 HU, confirming that the most considerable difference originates from VUE image
measurements, and not from the selection of monochromatic energy for DECT post-contrast
measurements. Selection of keV to represent 120 kVp images did not affect the results of the
experiment.

keV

CT number
Scenario III low
enhancement (HU)

SD

CT number Scenario
IV intermediate
enhancement (HU)

SD

65

39.6

2.9

54.9

3.0

68

37.1

3.0

53.1

3.1

69

36.4

3.1

52.5

3.2

70

35.9

3.1

52.0

3.2

71

35.4

3.1

51.7

3.3

72

34.5

3.2

51.0

3.4

75

33.1

3.3

49.8

3.5

Table 26. Assessment of the effect of variation in monochromatic energy selection (keV) on
CT number for the small phantom using GSI protocol 29
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4.3 Specific Aim 3
4.3.1 Results
Preliminary data for evaluation of the effect of ASIR level on CT number accuracy were
collected in Sub Aim 2.2. The purpose for collecting this data was to compare the TUE method
(60% ASIR with a soft filter) to the VUE method (0% ASIR with a standard filter) of image
reconstruction in the retrospective study to determine which method to use in Sub Aim 2.3. The
results of this study are shown in Table 27 and Figure 35.
0% ASIR Standard filter

60% ASIR Soft filter

Mean CT
Number

Mean
Noise

Mean CT
Number

Mean
Noise

% Difference
between mean
CT numbers

3 cm sphere insert

13.33

6.17

13.03

6.14

0.23

1 cm sphere insert

21.94

7.76

22.08

7.69

0.64

Spine (Delrin rod)

311.34

5.80

311.48

5.53

0.05

Phantom
background

-64.75

6.41

-64.66

5.79

0.14

ROI Section

Table 27. Comparison of retrospective study image reconstruction techniques

Technique comparison for 3 cm sphere

18
16
14

Noise (HU)

12
10
8
6
4

0% ASIR Std filter
60% ASIR Soft filter

2
0
0

10

20

30

40

50

60

GSI Preset

Figure 35. Comparison of retrospective study image reconstruction techniques
For Specific Aim 3, three levels of ASIR 0%, 60%, and 100% were chosen to assess the
effect of ASIR level on enhancement values. Subsets of experiments from Specific Aim 2.3 were
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chosen for reconstruction with the stated levels of ASIR. The results were fitted and analyzed
using a Bayesian Hierarchical model, the results of which are given in Table 28. The mean of the
slopes of ASIR level in relation to CT number for each phantom configuration is given as µASIR,
and the associated standard deviation, is given by σASIR. A slope approaching zero implies no
difference in CT number for changing ASIR level. The absolute value of the slope indicates the
most anticipated difference in CT number resulting from maximum possible difference in ASIR
level. For example a slope of -0.0168 implies that the maximum possible difference would be
1.68 HU.

Small
Patient
Medium
Patient
Large
Patient

Mean

SD

95% Confidence Interval

µASIR

-0.0168

0.0042

(-0.0252, -0.0084)

σASIR

0.0161

0.003

(0.0113, 0.023)

µASIR

-0.0174

0.0053

(-0.0278, -0.007)

σASIR

0.0201

0.0039

(0.0137, 0.029)

µASIR

-0.0258

0.0068

(-0.0394, -0.0126)

σASIR

0.0252

0.0053

(0.0166, 0.0372)

Table 28. Specific Aim 3 results

4.3.2 Discussion
Results of Sub Aim 3 indicate that there is no clinical significance resulting from
changing the level of ASIR applied to the reconstructed image on measured CT number. The
largest mean slope was -0.0258 for the large patient, which corresponds to a maximum
anticipated difference in CT number of 2.58 HU for any range of variation in ASIR level applied.
These results confirm the validity of the results from the quantitative retrospective study in
Specific Aim 1, despite the differences in reconstruction techniques. However, confirmation that
ASIR level does not quantitatively effect CT number does not validate the results of the
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qualitative study. ASIR level affects the perceived “graininess” or noise of the image, and
therefore very likely had an effect on the qualitative scores given by the radiologists for VUE
images (which had 0% ASIR) as compared to TUE images (which had 60% ASIR).

Figure 36. Visual comparison of variation in ASIR level: 0% (left), 60% (center), 100%
(right)
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Chapter 5. Conclusions
5.1 Specific Aim Conclusions
The results of the retrospective study indicate that VUE images have the potential to
replace TUE images clinically. In the qualitative study VUE images were found to be inferior to
TUE images for visualization of major vessels and depiction of liver parenchyma, which may be
attributed in part to the variation in reconstruction techniques. In the quantitative study VUE
images were found to be non-inferior to TUE images only in the liver, medulla, and cystic lesions
based on a paired t-test. However, after consideration of the clinical relevance of the results, VUE
images were determined to be non-inferior for the spleen and subcutaneous fat as well. An
important artifact observed in this study, referred to as the subtraction artifact, also affects the
feasibility of replacing TUE with VUE images because of the importance of the visibility of
calcifications in renal lesion characterization.
A phantom study was conducted to assess VUE images across a wide range of clinical
scenarios. The results indicate that enhancement values for VUE based measurements are not
significantly different from TUE based measurements for simulated AML lesions and benign
cystic lesions. However, the results for simulation of Bosniak category II-IV lesions indicated
that enhancement values are significantly different when using VUE as the baseline for
enhancement measurements. These results indicate that for borderline enhancing lesions VUE
images are not a suitable replacement for TUE images. Considering the purpose of diagnostic
renal CT, in which the lesion type is not known prior to imaging, VUE images are currently not
suitable for diagnosis of an unknown renal lesion type. Although the VUE images reconstructed
using the MSI algorithm in its current form likely cannot be used as a replacement for TUE
images, we believe the results of this study still prove the potential for this application.
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The impact of ASIR level on VUE enhancement accuracy was assessed in Specific Aim
3. The results from the mixed effects model indicate that the level of ASIR applied does not affect
measured CT numbers or enhancement. These results further validate the results of the quantitate
study in Specific Aim 1, despite the difference in reconstruction techniques between TUE and
VUE images.
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5.2 Future Work
Repeating a qualitative retrospective study with radiologists (Sub Aim 1.1) where the
reconstruction techniques between TUE and VUE images are identical would be valuable.
Preferably, these cases would involve more renal disease, since most cases used in this
retrospective analysis were patients with pancreatic indication and no associated renal lesions.
Additionally, a subset of images would be selected randomly for separate qualitative evaluation
of visualization of calcifications. For this study, TUE and VUE images would be shown side by
side, and the radiologists would compare intensity and number of calcifications visible in each
image.
Selecting a subset of experiments from Sub Aim 2.3, such as scenarios III-IV for repeated
analysis with blood used would allow for more direct evaluation of the clinical performance of
the algorithm.
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6. Appendix
6.1 Qualitative Questionnaire
Instructions: An image will be presented to you, which you can window/level to your preference.
Please choose one answer for each of the following questions to reflect your opinions as
accurately as possible for each image given.
Number of years of experience reading CT abdominal exams: _________
Survey
1. Visualization of major vessels (considering hepatic, portal, and renal veins in particular)
1.
2.
3.
4.
5.

Very poor
Poor
Adequate
Good
Very good

2. Visually sharp reproduction of the pancreatic contour
1.
2.
3.
4.
5.

Very poor
Poor
Adequate
Good
Very good

3. Visualization of calcifications
1.
2.
3.
4.
5.

Very poor
Poor
Adequate
Good
Very good

4. Depiction of liver parenchyma, e.g., ability to determination of the degree of fatty
infiltration
1.
2.
3.
4.
5.

Very poor
Poor
Adequate
Good
Very good

5. Visualization of adrenal glands
1.
2.
3.
4.
5.

Very poor
Poor
Adequate
Good
Very good

6. Corticomedullary differentiation
1.
2.
3.

No differentiation
Slight differentiation
Extreme differentiation
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6.2 Designs for each phantom
Small Phantom Design

Medium Phantom Design

Large Phantom Design
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6.3 Complete List of GSI Protocols used in Sub Aim 2.2.
GSI
Preset

SFOV

Rot time
(s)

Beam width
(mm)

mA

CTDIw
(mGy)

CTDIvol
0.531 pitch

CTDIvol
0.984 pitch

1

Large

0.5

40

630

17.49

32.94

17.77

51

Large

0.5

40

260

10.18

19.17

10.35

54

Large

0.6

40

275

8.96

16.87

9.11

15

Large

0.6

40

640

21.5

40.49

21.85

31

Large

0.6

40

375

12.72

23.95

12.93

40

Large

0.6

40

360

12.09

22.77

12.29

22

Large

0.7

40

375

14.79

27.85

15.03

44

Large

0.7

40

275

10.51

19.79

10.68

48

Large

0.7

40

260

8.91

16.78

9.05

10

Large

0.8

40

600

25.13

47.33

25.54

27

Large

0.8

40

550

23.19

43.67

23.57

36

Large

0.8

40

360

10.14

19.10

10.30

4

Large

0.9

40

600

28.47

53.62

28.93

5

Large

1.0

40

600

32.01

60.28

32.53

17

Large

0.6

20

640

23.41

44.09

23.79

33

Large

0.6

20

375

13.69

25.78

13.91

24

Large

0.7

20

375

15.87

29.89

16.13

12

Large

0.8

20

600

27.33

51.47

27.77

7

Large

1.0

20

600

34.87

65.67

35.44

3

Medium

0.5

40

630

18.33

34.52

18.63

52

Medium

0.5

40

360

10.59

19.94

10.76

16

Medium

0.6

40

640

22.46

42.30

22.83

32

Medium

0.6

40

375

13.61

25.63

13.83

41

Medium

0.6

40

360

12.86

24.22

13.07

55

Medium

0.6

40

375

9.51

17.91

9.66

23

Medium

0.7

40

375

15.56

29.30

15.81

45

Medium

0.7

40

375

11.1

20.90

11.28

49

Medium

0.7

40

260

9.54

17.97

9.70

11

Medium

0.8

40

600

26.27

49.47

26.70

28

Medium

0.8

40

550

24.6

46.33

25.00

37

Medium

0.8

40

260

10.81

20.36

10.99

6

Medium

1.0

40

600

33.43

62.96

33.97

79

35

Medium

0.5

20

630

19.85

37.38

20.17

53

Medium

0.5

20

360

11.51

21.68

11.70

18

Medium

0.6

20

640

24.42

45.99

24.82

34

Medium

0.6

20

375

14.16

26.67

14.39

42

Medium

0.6

20

360

14.07

26.50

14.30

56

Medium

0.6

20

275

10.34

19.47

10.51

25

Medium

0.7

20

375

16.76

31.56

17.03

46

Medium

0.7

20

275

11.99

22.58

12.18

50

Medium

0.7

20

260

10.24

19.28

10.41

13

Medium

0.8

20

600

28.58

53.82

29.04

29

Medium

0.8

20

550

26.74

50.36

27.17

38

Medium

0.8

20

260

11.69

22.02

11.88

2

Medium

0.9

20

600

32.32

60.87

32.85

8

Medium

1.0

20

600

36.34

68.44

36.93
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6.4 Phantom study image acquisition matrix examples
Patient
Size
Small

Lesion
Size
1 cm

Image
TUE
Postcontrast
TUE
Postcontrast
TUE
Postcontrast

2 cm

3 cm

Patient
Size
Medium

Lesion
Size
1 cm

2 cm

3 cm

Patient
Size
Large

Image
TUE
Postcontrast
TUE
Postcontrast
TUE
Postcontrast

Lesion
Size
1 cm

2 cm

3 cm

Image
TUE
Postcontrast
TUE
Postcontrast
TUE
Postcontrast

Table 29. SECT image acquisition checklist for each scenario

Patient
Size
SMALL

Lesion
Size
1 cm

GSI
preset
10

Patient
Size
MEDIUM

Lesion
Size

Thickness
(mm)

GSI
preset

Patient
Size

Lesion
Size

5

10

Large

1 cm

1 cm

3 cm

10

11

11

12

16

16

22

29

36

10

10

11

11

12

16

16

22

29

29

36

10

10

11

11

12

16

16

22

29

29

36

29
2 cm

GSI
preset

10

10

2 cm

5

3 cm

5

Table 30. DECT image acquisition checklist for each post-contrast scenario for VUE images
reconstruction
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6.5 Sub Aim 1 Results: Intra-observer variability between the radiologists

Intra-observer variability: Radiologist 1
5

Repeat 1
Repeat 2

Average Score

4
3
2
1
0

Figure 37. Intra-observer variability for Radiologist 1

Intra-observer variability: Radiologist 2

Average Score

5

Repeat 1
Repeat 2

4
3
2
1
0

Figure 38. Intra-observer variability for Radiologist 2

Intra-observer variability: Radiologist 3
5

Repeat 1
Repeat 2

Average Score

4
3
2
1
0

Figure 39. Intra-observer variability for Radiologist 3
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6.6 Phantom Study Simulation 1 graphs
The error bars for each graph represent ± the standard deviation for the results represented by
each bar in the graph.

TUE

VUE-11

TUE

Small

VUE-11
Medium

TUE

Periphery

Center

Periphery

Center

Periphery

Center

Periphery

Center

Periphery

Center

Variation in lesion position within the SFOV

Periphery

0
-20
-40
-60
-80
-100
-120
-140

Center

CT Number (HU)

Scenario 1

VUE-10
Large

Figure 40. Comparison of TUE vs. VUE enhancement values for variation of position of
lesion within the FOV for the 1 cm sphere and the specified GSI protocols.

Variation in lesion size

0

CT Number (HU)
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Figure 41. Comparison of TUE vs. VUE enhancement values for variation in phantom and
lesion sizes for the specified GSI protocols and lesions located in the periphery of the SFOV.
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Figure 42. Comparison of TUE vs. VUE enhancement values for variation in phantom size
for 2 cm lesion and the identified GSI protocols.
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Figure 43. Comparison of TUE vs. VUE enhancement values for variation of position of
lesion within the FOV for the 1 cm sphere and the specified GSI.
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Figure 44. Comparison of TUE vs. VUE enhancement values for variation in phantom and
lesion sizes for the GSI protocols specified and lesions located in the periphery of the SFOV.
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Figure 45. Overall comparison of low, intermediate, and high enhancement scenarios for a
40 HU baseline for the 3 cm lesions located in the periphery of the SFOV
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Small Phantom
Scenario

I and II

IV and V

Large Phantom

Mean

SD

Ext Val

Mean

SD

Ext Val

Mean

SD

Ext Val

β.VUE-10

0.159

0.8689

0.564

-0.0065

0.8878

0.502

-2.3863

3.2323

0.238

β.VUE-11 (12)

0.1644

0.8742

0.555

0.0605

0.8894

0.515

-2.2122

3.0847

0.25

β.VUE-16 (22)

0.1768

0.9766

0.56

0.2176

0.9704

0.56

-2.525

3.427

0.226

β.VUE-29 (36)

0.0786

0.8685

0.524

0.0977

0.8711

0.531

-1.8309

2.9779

0.273

-16.3479 0.9537

0

-13.8417

0.858

0

-7.5158

1.4429

0

β.VUE-11 (12) -16.4564 0.9552

0

-14.2445

0.863

0

-6.9222

1.4306

0

β.VUE-16 (22) -16.5018 0.9606

0

-14.0403 0.8465

0

-8.6903

1.3984

0

β.VUE-29 (36) -16.2392 0.9296

0

-14.3276 0.8613

0

-7.4961

1.4352

0

β.VUE-10
III

Medium Phantom

Protocol

β.VUE-10

-8.1564

1.1752

0

-9.0207

1.5786

0

-9.7155

1.7239

0

β.VUE-11 (12)

-9.722

1.2145

0

-10.1018 1.6279

0

-7.9408

1.7143

0

β.VUE-16 (22) -9.3679

1.2082

0

-9.4814

1.6648

0

-10.9021

1.765

0

β.VUE-29 (36)

1.2733

0

-8.8473

1.6781

0

-8.372

1.6895

0

-9.053

Table 31. Summary of the results for differences in enhancement measurements when using
VUE images (for each selected protocol) compared to TUE images as the baseline for
calculation of enhancement (where the mean and SD values are for the difference in
enhancement were computed in the Bayesian Hierarchical model, and are therefore not raw
differences). The GSI protocol which varied least from TUE enhancement measurements
for each scenario is highlighted.

86

7. Bibliography
1.

J. T. Bushberg, J.A.S., E. M. Leidholdt Jr, J. M. Boone, The Essential Physics of Medical
Imaging. 3rd ed. 2011, Philadelphia, Pa: Lippincott Williams and Wilkins.

2.

Kalender, W.A., X-ray computed tomography. Physics in medicine and biology, 2006.
51(13): p. R29.

3.

Coursey, C.A., R.C. Nelson, D.T. Boll, E.K. Paulson, L.M. Ho, A.M. Neville, D. Marin,
R.T. Gupta, and S.T. Schindera, Dual-energy multidetector CT: how does it work, what
can it tell us, and when can we use it in abdominopelvic imaging? 1. Radiographics,
2010. 30(4): p. 1037-1055.

4.

Brooks, R.A. and G. Di Chiro, Theory of Image Reconstruction in Computed
Tomography 1. Radiology, 1975. 117(3): p. 561-572.

5.

Huda, W. and R.M. Slone, Review of radiologic physics. 2003: Lippincott Williams &
Wilkins.

6.

Johnson, T.R., B. Krauss, M. Sedlmair, M. Grasruck, H. Bruder, D. Morhard, C. Fink, S.
Weckbach, M. Lenhard, and B. Schmidt, Material differentiation by dual energy CT:
initial experience. European radiology, 2007. 17(6): p. 1510-1517.

7.

Marin, D., D.T. Boll, A. Mileto, and R.C. Nelson, State of the Art: Dual-Energy CT of
the Abdomen. Radiology, 2014. 271(2): p. 327-342.

8.

N. Chandra, D.A.L., T. R. C. Johnson, Gemstone Detector: Dual Energy Imaging via
Fast kVp Switching, in Dual Energy CT in Clinical Practice. 2011, Medical Radiology. p.
35-41.

9.

Graser, A., T.R. Johnson, E.M. Hecht, C.R. Becker, C. Leidecker, M. Staehler, C.G.
Stief, H. Hildebrandt, M.C. Godoy, and M.E. Finn, Dual-energy ct in patients suspected
of having renal masses: Can virtual nonenhanced images replace true nonenhanced
images? 1. Radiology, 2009. 252(2): p. 433-440.

87

10.

Mendonça, P.R., R. Bhotika, M. Maddah, B. Thomsen, S. Dutta, P.E. Licato, and M.C.
Joshi. Multi-material decomposition of spectral CT images. in SPIE Medical Imaging.
2010. International Society for Optics and Photonics.

11.

Alvarez, R.E. and A. Macovski, Energy-selective reconstructions in x-ray computerised
tomography. Physics in medicine and biology, 1976. 21(5): p. 733.

12.

Kalender, W.A., W. Perman, J. Vetter, and E. Klotz, Evaluation of a prototype dual‐
energy computed tomographic apparatus. I. Phantom studies. Medical physics, 1986.
13(3): p. 334-339.

13.

Chandra, N., Material Attenuation Coefficient in GE presentation, D.E. Physics, Editor.

14.

Xu, D., D.A. Langan, X. Wu, J.D. Pack, T.M. Benson, J.E. Tkaczky, and A.M. Schmitz.
Dual energy CT via fast kVp switching spectrum estimation. in SPIE Medical Imaging.
2009. International Society for Optics and Photonics.

15.

Bosniak, M.A., Diagnosis and management of patients with complicated cystic lesions of
the kidney. AJR. American journal of roentgenology, 1997. 169(3): p. 819-821.

16.

Bosniak, M.A., The current radiological approach to renal cysts. Radiology, 1986.
158(1): p. 1-10.

17.

Israel, G.M. and M.A. Bosniak, How I Do It: Evaluating Renal Masses 1. Radiology,
2005. 236(2): p. 441-450.

18.

Israel, G.M. and M.A. Bosniak, Pitfalls in Renal Mass Evaluation and How to Avoid
Them 1. Radiographics, 2008. 28(5): p. 1325-1338.

19.

E. Cho, H.O.A., P. Lindblad, Epidemiology of Renal Cell Carcinoma. Hematology/
Oncology Clinics 25(4): p. 651-665.

20.

Institute, N.C., SEER Stat Fact Sheets: Kidney and Renal Pelvis Cancer, Surveillance
Research Program: http://seer.cancer.gov/statfacts/html/kidrp.html.

21.

G. M. Israel, M.A.B., An Update of the Bosniak Renal Cyst Classification System.
Urology, 2005. 66: p. 484-488.
88

22.

Pooler, B.D., P.J. Pickhardt, S.D. O’Connor, R.J. Bruce, S.R. Patel, and S.Y. Nakada,
Renal cell carcinoma: attenuation values on unenhanced CT. American Journal of
Roentgenology, 2012. 198(5): p. 1115-1120.

23.

Song, C., G.E. Min, K. Song, J.K. Kim, B. Hong, C.-S. Kim, and H. Ahn, Differential
diagnosis of complex cystic renal mass using multiphase computerized tomography. The
Journal of urology, 2009. 181(6): p. 2446-2450.

24.

Macari, M. and M.A. Bosniak, Delayed CT to Evaluate Renal Masses Incidentally
Discovered at Contrast-enhanced CT: Demonstration of Vascularity with
Deenhancement 1. Radiology, 1999. 213(3): p. 674-680.

25.

J. K. Kim, S.Y.P., J. H. Shon, K. S. Cho, Angiomyolipoma with Minimal Fat:
Differentiation from Renal Cell Carcinoma at Biphasic Helical CT. Radiology, 2004.
230: p. 677-684.

26.

C. W. Yang, S.H.S., Y. H. Chang, H. J. Chung, J. H. Wang, A. TL. Lin, K. K. Chen, Are
there useful CT features to Differentiate Renal Cell Carcinoma from Lipid-Poor Renal
Angiomyolipoma? AJR. American journal of roentgenology, 2013. 201(5): p. 1017-28.

27.

Maddah, M., P.R. Mendonça, and R. Bhotika. Physically meaningful virtual unenhanced
image reconstruction from dual-energy CT. in Biomedical Imaging: From Nano to
Macro, 2010 IEEE International Symposium on. 2010. IEEE.

28.

Song, K.D., C.K. Kim, B.K. Park, and B. Kim, Utility of iodine overlay technique and
virtual unenhanced images for the characterization of renal masses by dual-energy CT.
American Journal of Roentgenology, 2011. 197(6): p. W1076-W1082.

29.

Barrett, T., D. Bowden, N. Shaida, E. Godfrey, A. Taylor, D. Lomas, and A. Shaw,
Virtual unenhanced second generation dual-source CT of the liver: is it time to discard
the conventional unenhanced phase? European journal of radiology, 2012. 81(7): p.
1438-1445.

89

30.

De Cecco, C.N., A. Darnell, N. Macías, J.R. Ayuso, S. Rodríguez, J. Rimola, M. Pagés,
Á. García-Criado, M. Rengo, and A. Laghi, Virtual unenhanced images of the abdomen
with second-generation dual-source dual-energy computed tomography: image quality
and liver lesion detection. Investigative radiology, 2013. 48(1): p. 1-9.

31.

Moon, J., B. Park, C. Kim, and S. Park, Evaluation of virtual unenhanced CT obtained
from dual-energy CT urography for detecting urinary stones. Evaluation, 2012. 85(1014).

32.

Takahashi, N., R.P. Hartman, T.J. Vrtiska, A. Kawashima, A.N. Primak, O.P. Dzyubak,
J.N. Mandrekar, J.G. Fletcher, and C.H. McCollough, Dual-energy CT iodine-subtraction
virtual unenhanced technique to detect urinary stones in an iodine-filled collecting
system: a phantom study. AJR. American journal of roentgenology, 2008. 190(5): p.
1169.

33.

Sommer, C.M., C.B. Schwarzwaelder, W. Stiller, S.T. Schindera, U. Stampfl, N.
Bellemann, M. Holzschuh, J. Schmidt, J. Weitz, and L. Grenacher, Iodine removal in
intravenous dual-energy CT-cholangiography: Is virtual non-enhanced imaging effective
to replace true non-enhanced imaging? European journal of radiology, 2012. 81(4): p.
692-699.

34.

Pache, G., B. Krauss, P. Strohm, U. Saueressig, P. Blanke, S. Bulla, O. Schäfer, P.
Helwig, E. Kotter, and M. Langer, Dual-Energy CT Virtual Noncalcium Technique:
Detecting Posttraumatic Bone Marrow Lesions—Feasibility Study 1. Radiology, 2010.
256(2): p. 617-624.

35.

Reagan, A.C., P.I. Mallinson, T. O’Connell, P.D. McLaughlin, B. Krauss, P.L. Munk, S.
Nicolaou, and H.A. Ouellette, Dual-Energy Computed Tomographic Virtual Noncalcium
Algorithm for Detection of Bone Marrow Edema in Acute Fractures: Early Experiences.
Journal of computer assisted tomography, 2014.

36.

Yamada, S., T. Ueguchi, T. Ogata, H. Mizuno, R. Ogihara, M. Koizumi, T. Shimazu, K.
Murase, and K. Ogawa, Radiotherapy treatment planning with contrast-enhanced
90

computed tomography: feasibility of dual-energy virtual unenhanced imaging for
improved dose calculations. Radiation Oncology, 2014. 9(1): p. 1-10.
37.

Graser, A., C.R. Becker, M. Staehler, D.A. Clevert, M. Macari, N. Arndt, K. Nikolaou,
W. Sommer, C. Stief, and M.F. Reiser, Single-phase dual-energy CT allows for
characterization of renal masses as benign or malignant. Investigative radiology, 2010.
45(7): p. 399-405.

38.

L. Wang, B.L., X. Wu, J. Wang. Y. Zhou, W. Wang, X. Zhu, Y. Yu. X. Li, S. Zhang, Y.
Shen, Correlation between CT attenuation value and iodine concentration in vitro:
Discrepancy between gemstone spectral imaging on single-source dual-energy CT and
traditional polychromatic X-ray imaging. Journal of Medical Imaging and Radiation
Oncology, 2012. 56: p. 379-383.

39.

A. Jonisch, A.N.R., P. G. Mutalik, G. M. Israel, Can High-Attenuation Renal Cysts be
Differentiated from Renal Cell Carcinoma at Unehanced CT? Radiology, 2007. 243(2):
p. 445-450.

40.

R. Vikram, C.S.N., P. Tamboli, N. M. Tannir, E. Jonasch, S. F. Matin, C. G. Wood, C.
M. Sandler, Papillary Renal Cell Carcinoma: Radiologic-Pathologic Correlation and
Spectrum of Disease. RadioGraphics, 2009. 29: p. 741-757.

41.

Taylor, J.R., An Introduction to Error Analysis: the study of uncertainties in physical
measurements. Second Edition ed. 1982: Maple-Vail book manufacturing group.

42.

Viera, A.J. and J.M. Garrett, Understanding interobserver agreement: the kappa statistic.
Fam Med, 2005. 37(5): p. 360-363.

43.

Toepker, M., T. Moritz, B. Krauss, M. Weber, G. Euller, T. Mang, F. Wolf, C.J. Herold,
and H. Ringl, Virtual non-contrast in second-generation, dual-energy computed
tomography: reliability of attenuation values. European journal of radiology, 2012.
81(3): p. e398-e405.

91

44.

D. Zhang, X.L., B. Liu, Objective characterization of GE Discovery CT750 HD scanner:
Gemstone spectral imaging mode. Med Phys, 2011. 38: p. 1178-1188.

45.

M. Goodsitt, E.G.C., S. C. Larson, Accuracies of the synthesized monochromatic CT
numbers and effective atomic numbers obtained with a rapid kV switching dual energy
CT scanner. Med Phys, 2011. 38(4): p. 2222-2232.

92

8. Vita

Dawn Olivia Popnoe was born in New Port Richey, Florida on May 10, 1991, the
daughter of Mark Thomas Skeen and Victoria Marie Skeen. After graduating Valedictorian of
Okeechobee High School, Okeechobee, Florida in 2009 she entered Angelo State University in
San Angelo, Texas. She received Bachelor of Science degrees with a major in Physics and a
major in Mathematics. In August of 2013 she entered the Medical Physics Master’s program at
The University of Texas Graduate School of Biomedical Sciences at Houston. After graduation,
Olivia plans to continue her education by pursing a Doctorate of Medical Physics at the
University of Texas Health and Science Center in San Antonio, Texas.

Permanent Address:
608 N 23rd St
Lamesa, Tx 79331

93

